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ABSTRACT
Introduction: Epidemiology studies often rely on maternal self-reports for drug use
information, however, the degree of drug use under-reporting among pregnant women is
largely unknown. The purpose of this study is to assess the accuracy of self-reports for
methadone, buprenorphine, opioids (prescription opioids and heroin), marijuana,
benzodiazepines, amphetamines/methamphetamines, and cocaine/crack-cocaine in a
population of pregnant women.
Methods: Analysis was based on 102 pregnant women enrolled in the 'Biomarkers in
Pregnancy Study' (BIPS) cohort at the University of New Mexico. Women attending the
UNM Milagro clinic, designated to pregnant women with the current or past history of
substance abuse, were enrolled during one of the first prenatal care visits and followed up
to term. Self-reported information about drug use was compared with the results of the
urine drug screens conducted during the third trimester. Simple kappa and prevalenceand-bias-adjusted kappa coefficients were calculated as measures of agreement.
Sensitivity and specificity of self-reports for each drug class were also estimated using
iii

urine toxicology screening as the gold standard. In addition, logistic regression was
conducted to evaluate the effect of number of toxicology screens on agreement.
Results: The mean maternal age of the sample was 26.4 ± 4.9 years and included a large
proportion of ethnic minority (78% Hispanics/Latina) and socially disadvantaged (51% <
less than high school education and 95% Medicaid-insured) pregnant women. On
average, these patients had 4.8 ± 3.0 urine drug screens in the third trimester. For
methadone-maintenance therapy, there was a perfect agreement between self-reports and
urine screens (k and PABAK =1.0, 100% sensitivity and specificity). Simple kappa
coefficients for other classes of drugs revealed varied levels of agreement, however,
PABAK coefficients indicated moderate to almost perfect agreement for other classes of
drugs. Sensitivity of self-reports was low for all classes of drugs, with marijuana and
opioids more acceptable than other classes of drugs. The specificity of self-report was
high for classes of drugs. Logistic regression revealed no association between number of
toxicology screens and agreement.
Discussion: These results indicated that sensitivity of self-reports for all classes of drugs
was low with opioids and marijuana more acceptable than other drugs.
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CHAPTER 1: INTRODUCTION
1.1. Background
According to the 2011 annual National Survey on Drug Use and Health conducted by the
Substance Abuse and Mental Health Services Administration1, approximately 22.5
million Americans reported using an illicit drug or psychotherapeutic medications such as
pain reliever, tranquilizer or stimulant in the month prior to the survey. This number has
increased by 8.3 percent from the previous estimates of the year 2002. Results of the
survey indicated that marijuana was the most commonly abused illicit drug with an
estimated 18.1 million current users in the year 2011. The survey also reported that
prescription drug abuse, that is the non-medical use of prescription drugs, was the second
most prevalent illicit drug use category and approximately 2.7% of the US population
reported taking prescription drugs non-medically. The most commonly abused
medications included pain reliever, tranquilizers, stimulants, and sedatives. In addition,
high rates of other risky behaviors were also reported among those who abused drugs1.
Implications of the illicit drug use epidemic and its consequences are significant. It is a
serious public health concern that presents tremendous burden on both individuals and
society, estimable in terms of morbidity, mortality, untoward health and medical
consequences, societal and economic costs associated with the addiction and its
consequences. Alcohol and other substances of abuse including marijuana, LSD, heroin,
cocaine, tobacco and prescription drugs account for nearly 590,000 deaths in the US
every year2. Apart from high mortality rates, drug use and addiction is associated with
high morbidity causing approximately 40 million illnesses and injuries each year2. The
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economic burden of substance use is estimated to be greater than $600 billion every year,
which includes health care costs, lost productivity and crimes3,4. Societal costs
measurable in terms of social costs to families and communities include family violence,
initiation of substance abuse among children of drug addict parents, crimes, passive
exposure, accidents, and divorce.2
Substance abuse among pregnant women is most alarming and poses complex
management issues for the healthcare system. Data from the National Survey on Drug
Use and Health shows that the prevalence of drug use among pregnant women aged 1544 years was 5.0% averaged for the years 2010 and 20115. The use of illicit drugs among
younger pregnant women was substantially higher with 20.9 percent drug users among
pregnant women aged 15 to 17, 8.2 percent among pregnant women aged 18 to 25, and
2.2 percent among pregnant women aged 26 to 44 combined for the years 2010 and 2011.
Drug use during pregnancy has serious complications for both the mothers and the
exposed fetuses. Various long-term prospective and retrospective studies have shown
high risks of morbidity rates in substance abusing pregnant women and their offsprings6
7

. In brief, teratogenic agents such as opioids and cocaine are associated with an increased

risk of miscarriages, pre-mature births, congenital birth defects, various long-term and
short-term health, behavioral and cognitive problems7,8. These agents exert their effects
directly by either passing through the placenta and interfering with the fetal development
or indirectly due to poor and irresponsible maternal behavior and associated postnatal
environment.7-10 The gravity of drug use during pregnancy and its associated
consequences make it imperative for researchers to accurately identify all drug use during
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pregnancy by assessing the validity of frequently employed drug use methods and
ensuring that the methods employed for the same are of high validity.
Methods such as self-report and biochemical analysis of bodily fluids are available to
assess maternal consumption of substances during pregnancy11. Each method has its own
advantages and disadvantages. Based on the availability of resources and research design,
one of the two methods can be employed to assess drug use during pregnancy.
Self-report represents a popular and commonly used method of data collection in social
and health services research. Self-reports are easy to administer, not only in face-to-face
to interviews but also by mail, telephone, or as self-administered questionnaires.
Compared to biochemical analysis of bodily fluids and parts, self-reported data is less
expensive to collect and at times, it may be the only mode to gather information about
subjective research questions, such as perceptions and behaviors of the study population.
Self-reports can be used for not only providing information about drug use but also
frequency and time-period of drug use, if disclosed by the respondents.
However, information collected by self-reports can be highly unreliable if special
emphasis is not given to the factors that can influence the response such as wording of the
interviews, expectations of the interviewer, anonymity, use of audio-visual aids in the
data collection etc.12 Moreover, information collected by self-reports are highly
susceptible to various validity issues. The concept of validity relates to the question "Are
we measuring what we intend to measure" and one of the important type of validity is
criterion validity, which in this study, refers to the extent to which the subjective selfreported data are verified by agreement with another indicator of the same phenomenon
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believed to be of higher validity13. One of the factors that can undermine the validity of
self-reported drug use during pregnancy is social desirability bias, which refers to the
unwillingness of the respondents to respond accurately for behaviors that might be
disapproved by the society. According to the social desirability theory, the more highly
stigmatized and negatively sanctioned a behavior, the stronger the tendency to deny
having engaged in that. This outlook indicates that unreliable reports, either
underreported or over reported may occur as a result of the perceived acceptability of the
correct response 13.
Due to advancements in drug screening techniques, various measures including analysis
of bodily fluids such as urine, saliva, meconium (first stool of an infant) and hair assays
are available for assessing the validity of self-reported drug use 11. Precision and accuracy
of these drug screening techniques make them ideal comparators for establishing the
validity of self-reports by comparing the sensitivity and specificity of self-reports with
any of the available above-mentioned objective methods. As legitimate and reasonable
concerns regarding the validity of self-reported maternal drug use during pregnancy exist,
it is incumbent upon researchers to address these issues. Therefore, the objective of this
study is to assess the validity of self-reported drug use during pregnancy using urine
toxicology screen results as the criterion.
1.2. Significance
Drug use during pregnancy is associated with various developmental and neurobehavioral
dysfunctions among prenatally exposed infants which makes it essential to accurately
assess the prevalence of drug use during pregnancy7. Timely identification of pregnant
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women with substance abuse behavior and exposed infants would help in the delivery of
timely clinical and behavioral interventions. In the absence of good quality evidence on
the validity of most commonly employed methods in assessing the drug abuse during
pregnancy, the interventions might not reach the exposed women and infants. This study
would enable the researchers in establishing the validity of self-reported information and
would answer if relying on self-reported information for risky behaviors like drug use
during pregnancy is adequate or not.
Reliable self-reports can be very helpful in assessing the effectiveness and compliance of
various substance abuse treatment and rehabilitative programs as they are easy to obtain
and relatively less expensive than the laboratory measures, provided their validity has
been established.
Very few studies in the past have compared the validity of self-reported data against
laboratory tests but methodological issues such as time-frames, number of biological
samples exist. Moreover, there is a dearth of comprehensive data specifically looking at
self-reported drug use during pregnancy among high-risk population of pregnant women.
Our study aims at comparing the validity of self-reported drug use using urine toxicology
screens as the criterion, stratifying results by different drug classes and in a population of
pregnant women with current or past history of substance abuse enrolled in a substance
abuse treatment clinic. Findings of this study would contribute to the limited knowledge
that exists in the literature about the agreement of self-reported drug use during
pregnancy with an objective measure.

5

1.3. Specific Aims and Hypothesis

SPECIFIC AIM I: To estimate the agreement between patient self-reports and urine
toxicology screens for the following classes of drugs: marijuana, methadone, prescription
opioids and heroin, amphetamines, cocaine, and benzodiazepines in a high-risk
population of pregnant women with substance use history.
We hypothesize that the agreement between two measures would be substantial
for this population as these women are on opioid maintenance therapy and receiving
treatment for their substance abuse behaviors. Therefore, they would be indeed honest in
reporting their consumption of drugs during pregnancy.
SPECIFIC AIM II: To compare the validity of self-reports for drug use by comparing the
sensitivity of self-report for different classes of drugs.
We hypothesize that the validity of self-report would diminish with increased
social undesirability of the drug used during pregnancy.

6

CHAPTER 2: LITERATURE REVIEW
The chapter will provide an overview of previous studies relevant to this topic and is
divided into three sections as follows:
1. Negative Consequences of drug use during pregnancy: This section of the literature
review begins with a brief summary on the effects of drug use during pregnancy on fetal
development followed by studies that have demonstrated negative consequences of
maternal drug use during pregnancy on the neonatal outcomes and later child growth and
development. This section will summarize the negative consequences of only those drugs
whose self-reports are evaluated for their validity in this study.
2. Validity of self-reports for smoking and alcohol use among pregnant women: This
section will summarize the studies that have assessed the accuracy of self-reports for
behaviors such as smoking and alcohol use among pregnant women.
3. Validity of self-reports for drug use during pregnancy compared to an objective
measure: This section of the literature will summarize studies that have assessed the
validity of self-reports for drug use during pregnancy. This section is then further divided
according to the criterion used for validation of self-reports. It begins with studies that
have evaluated the agreement between self-reports and urinalysis followed by studies
using meconium, hair or umbilical cord analysis.
2.1. Negative Consequences of Drug Use during Pregnancy
2.1.1. Teratogenic effects of drugs
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The teratogenic effects of drugs vary temporally and the susceptibility of the fetus to
various physiologic, teratogenic, and developmental abnormalities depends on the period
of exposure, dose of exposure, chronicity of exposure as well as interactional effects of
polydrug use during pregnancy14. Different organs have different critical periods of
vulnerability for malformations during the length of pregnancy, the heart is most
sensitive during the third and fourth weeks of gestation, whereas external genitalia during
the eighth and ninth weeks. Brain and skeleton are sensitive from the beginning of the
third week to the end of pregnancy and in the post birth period. Evidence suggests that
early exposure during pregnancy is associated with outcomes that are more deleterious
and first 3 months of gestation are most critical for teratogenic malformations. However,
changes caused by illicit or licit drugs may even occur later in pregnancy. Hence, timing
of exposure during pregnancy has different effects on different organs as exposure to a
drug at 24th week of gestation may not have as severe effects on heart as on the brain or
the skeleton compared to exposure at early gestation14.
2.1.2. Drug Use during Pregnancy and Infant Outcomes

COCAINE
The 'Crack baby' phenomenon led cocaine/ crack (crystals of cocaine that can be smoked)
cocaine to be the most extensively studied drug of abuse for adverse neonatal outcomes.
Studies have demonstrated the association of prenatal cocaine exposure with reduced
intrauterine fetal growth leading to low weight, height and head circumference at
birth,6,9,15-25 increased risk of preterm births,9,23-25 increased prevalence of small-forgestational age (SGA) infants,25 placental abruptions and premature rupture of
membranes,9 neurosonographic and morphological abnormalities,25-27 increased
8

healthcare utilization,28 and increased mortality.6 Prenatal cocaine exposure has also been
associated with the disruption of monoaminergic neurotransmitter systems29 during fetal
development affecting attention and behavioral regulation during early childhood. Studies
have documented adverse effects of prenatal cocaine exposure on language,30-41
executive function development such as cognition, attention, memory42-44 and on the
most crucial component inhibitory control, which refers to better emotional regulation,
reasoning and ability to maintain efforts toward attainment of goals45 while ineffective
inhibitory control is associated with the development of psychopathology (e.g. ADHD)
and various externalizing and internalizing difficulties.44,46,47
Despite the results of above mentioned studies, there is little consensus regarding the
adverse effects of cocaine use on pregnancy outcomes. A systematic literature review
conducted by Franks et. al.48 reviewed physical growth, cognition, language skills, motor
skills, and behavior, attention, affect, and neurophysiology outcomes in early childhood
after prenatal cocaine exposure. This review concluded that there was no consistent
negative correlation between prenatal cocaine exposure and physical growth,
developmental test scores, or receptive or expressive language. The study found no effect
of cocaine on behavior scores; however, less optimal motor scores upto the age of 7
months were reported among the exposed. Moreover, an association between prenatal
cocaine exposure and decreased attentiveness, emotional expressivity, neurophysiologic
and attention was suggested. Lutiger et. al.49 evaluated reproductive effects of maternal
cocaine use in a meta-analysis and concluded that very few adverse effects such as
genitourinary tract malformations could be significantly associated with the cocaine use
during pregnancy when polydrug users using cocaine were compared with polydrug users
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without cocaine use. Comparison of cocaine alone users and no drug users, revealed a
higher risk of in-utero deaths, and genitourinary tract malformations. In addition, analysis
of head circumference, gestational age, birth weight, and length revealed medium effect
size when cocaine users were compared with no drug users. However, when polydrug
with cocaine users were compared with polydrug without cocaine users yielded small to
non-existent effect size49.

OPIOIDS
Neonatal abstinence syndrome, NAS, a generalized disorder characterized by signs and
symptoms of central nervous system hyperirritability, gastrointestinal dysfunction,
respiratory distress and vague autonomic symptoms including yawning, sneezing,
mottling, and fever is a serious consequence of maternal opioid use during pregnancy50.
Prenatally exposed infants become passively addicted to the in-utero exposures and
undergo abstinence at birth. Infants born to opioid dependent mothers are at a risk of
NAS,51,52 longer length of stay in neonatal units, increased healthcare costs51 along with
outcomes like increased mortality, low birth weight, preterm births, antepartum
hemorrhage.51,53-59
The use and abuse of pain relieving medications, opioid analgesics, is increasing60,61 and
their use during pregnancy pose a serious public health challenge. A recent study by
Broussard et. al. evaluated the association between maternal opioid use between one
month before pregnancy and first trimester with birth defects in 17,449 cases and 6,701
controls. The study found significant association between opioid use during pregnancy
and birth defects like conoventricular septal defects, pulmonary valve stenosis,
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atrioventricular septal defects, hypoplastic left heart syndrome, spina bifida, or
gastroschisis in infants.62 Previous studies have reported the association of opioid use
during pregnancy with orofacial clefts, congenital heart defects (CHD)63,64 . However, the
study conducted by Shaw et. al., on the other hand found no association between opioids
and birth defects.65
Opioid maintenance therapy (OMT) used in opioid-dependent pregnant women is
associated with adverse neonatal outcomes when compared to drug free healthy
controls;53,59 however, studies have found significantly improved neonatal outcomes in
women receiving medically supervised doses of methadone or buprenorphine compared
to pregnant women abusing illicit opioids during their pregnancy.51,52,66

MARIJUANA
According to a review conducted by Kuczkowski67, although marijuana is not a wellknown human teratogen, recent studies suggested subtle negative effects of marijuana use
during pregnancy on neurobehavioral outcomes of the exposed infants including sleep
disturbances, impaired visual problem-solving, hyperactivity, inattention and increased
delinquency. Low neonatal birth weight, increased complication during labor and
increased proportion of preterm births were associated with maternal marijuana use
during pregnancy.
Similarly, another review conducted by Minnes et. al.8 stated that marijuana use during
pregnancy is not associated with any major fetal growth or physical abnormalities,
however, mild withdrawal and poor autonomic control have been observed in the
exposed infants. Prenatally exposed children exhibit deficits in reading, spelling, and
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higher order thinking including memory, planning, impulsivity, problem solving, and
attention. However, there was no overall suppression of IQ in the exposed infants. In
terms of long term behavioral and emotional consequences of prenatally exposed infants',
the authors concluded that there might be an increased risk of depressive symptoms and
adolescent substance abuse.8,68

METHAMPHETAMINES
Some studies reported that prenatal methamphetamine exposure was associated with a 3.5
times greater risk of SGA and had lower birth weight than controls.8 Other adverse
outcomes might included lower arousal from sleep, lack of energy, and withdrawal
symptoms, cleft palate, cranial abnormalities, fetal growth retardation, and behavioral
problems.8,69

BENZODIAZEPINES
According to a review conducted by McElhatton et.al.,70 the information regarding the
effect of benzodiazepines during pregnancy is limited and inconsistent. Earlier studies
have indicated an increased risk of multiple malformations, including facial clefts, and
cardiac malformations. However, later studies found no evidence of increased
malformations among infants of benzodiazepines users and had normal postnatal
development70. Another meta-analysis yielded an odds ratio of 1.07 for their fetal safety.
The authors concluded that while benzodiazepines do not increase teratogenic risks in
general but there is a two-fold increased risk of clefts with the use of benzodiazepines
during pregnancy.71
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Summary
Undeniably, substance abuse during pregnancy has serious implications for the
developing fetus. Various complications like restricted intrauterine growth, congenital
birth defects, preterm labor and delivery, placental rupture and abruptions, arise from
their use during pregnancy. Moreover, exposed infants are at an increased vulnerability to
cognitive and behavioral problems in the later stages of life. The overall adverse effects
of drug use are complex, multifactorial, and not well understood. The observed outcomes
could be due to a number of behavioral, social, psychological factors like postnatal
environment, role of parents, their lifestyle and personality, polysubstance abuse, and
nutritional status among others. The adverse outcomes associated with a specific illicit
drug are difficult to disentangle from the contributing psychosocial and lifestyle factors.
Polydrug exposure, home-environment, and maternal/paternal variables make it difficult
to attribute untoward consequences to one exposure.
Large-scale studies, with adequate sample size and control group, in variety of
environmental conditions are required in order to fully understand the influences of
various substances of abuse on the developmental stages of the exposed infants. In
addition, studies assessing the contributing effects of various substances are required in
future.

2.2. Validity of Self-Reports for Smoking and Alcohol Use during Pregnancy
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Studies assessing the accuracy of self-reports for smoking and alcohol use during
pregnancy are limited. The validity of self-reported smoking status during pregnancy was
compared with urinary/serum cotinine levels or carbon monoxide levels. Gilligan et. al.72
analyzed urine samples of women attending an antenatal care clinic for cotinine levels
and found that 17% of women positive for cotinine levels had misreported their smoking
status as non-smokers. Shipton et. al.73 concluded that merely relying on self-reported
smoking status during pregnancy led to an underestimation of true smoking prevalence
by 25% when compared to cotinine concentration in the blood samples. Similarly,
Britton et.al.74 estimated that 34.7% of women with positive urinary cotinine levels
denied smoking in their self-reports. Ford et.al.75 compared self-reported smoking status
collected through postal questionnaires with blood samples and smoking status recorded
in obstetric clinic retrospectively. The authors recorded underreporting, as cotininevalidated smoking prevalence was 31.3% and 27.7% whereas self-reported prevalences
were 19.2% and 15.7% for first and third trimester respectively, and 18.9% from clinic
records. Burstyn et. al.76 estimated sensitivity and specificity of self-reported smoking
status using urinary cotinine assays and found poor sensitivity (47%) and high specificity
(95%). Gollenberg et. al.77 assessed the validity of retrospectively reported risky maternal
behaviors while trying to get pregnant. Prospective longitudinal data recorded in daily
diaries, considered here as the gold standard were compared to self-reported smoking
(k=0.43), caffeine (k=0.21), alcohol (k=0.20), and fish consumption (k=0.32). The study
found poor to moderate validity of self-reported behaviors.
Despite substantial underreporting observed in the above-mentioned studies, few studies
reported moderate agreement between self-reported smoking status and an objective
14

measure. Klebanoff et.al.78 reported a high kappa coefficient of 0.83 representing
substantial agreement between self-reported smoking and cotinine assays. In this study,
95% self-reported non-smokers and 87% self-reported smokers revealed their accurate
smoking status, thus yielding a high correlation between the two measures. Authors of
this study concluded that self-reports during pregnancy are sufficiently accurate and little
would be gained using biochemical verification. This study utilized self-reported
smoking status and serum samples collected 30 years ago. Secker Walker et. al.79
examined correlations between self-reported smoking, exhaled carbon monoxide (CO)
and cotinine levels at first and thirty-sixth week prenatal visits. Correlations between selfreported smoking and CO levels were 0.65 and 0.70 at the two visits whereas for
cotinine/creatinine ratio, the correlations were slightly lower, 0.61 and 0.65 for the two
visits, respectively indicating high correlation between self-reports and exhaled CO
levels.
Rice et.al80 examined agreement between maternal reports and medical records for a
variety of perinatal behaviors. Authors reported good agreement for smoking between
maternal reports and medical records (k=0.80), whereas agreement for alcohol use was
poor (k=0.17). In another study conducted by Fox et.al81, authors assessed the reliability
of self-reports for smoking habits and alcohol consumption patterns during pregnancy for
pregnant women participating in a randomized clinical trial of smoking cessation
intervention. This study employed a test-retest design and study participants provided
self-reports of their smoking and alcohol consumption prior to 18th week (15.8±3.8
weeks) and then again at 18th week of gestation. Self-reported information was compared
with thiocyanate levels in their saliva samples collected during the first interview. In this
15

study, about half of the subjects gave identical reports of pregnancy smoking habits at
test and retest and rest were minor changes. Kappa statistic for smoking status in both the
groups was similar, 0.61 in the intervention and 0.56 in the control group. Similarly, for
alcohol drinking patterns, kappa coefficient was 0.52 in the intervention group and 0.56
in the control group.
In a study conducted by Hessol et. al.82, the authors interviewed 350 Latinas above 20
weeks of gestation regarding their alcohol, smoking, and medical conditions. The authors
reported low kappa coefficient for self-reported alcohol use and medical records (k=0.35)
whereas moderate kappa coefficient for tobacco use (k=0.79). Self-reports had lowest
validity for alcohol use whereas moderate validity for tobacco use.

2.3. Validity of Self-Reports for Drug Use during Pregnancy

Limited numbers of studies have assessed the validity of self-reported illicit drug use
during pregnancy using toxicology screens as the criterion. The common methods used
were urinalysis, hair, meconium, or umbilical cord analysis. In the following section,
studies evaluating the agreement between self-report with any of the above-mentioned
objective measures are summarized:
2.3.1. Self-Reports and Urinalysis
Six studies have used urine toxicology screens to validate self-reported drug use during
pregnancy and majority of them assessed agreement for cocaine use and marijuana.
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Marroun et.al.83 assessed the agreement between self-reported prenatal cannabis use and
urinalysis among pregnant women enrolled in a population based birth cohort titled as the
Generation R study. Self-reported maternal substance use, that is, alcohol, tobacco, and
cannabis was measured using a questionnaire at the time of enrollment in the first
trimester of the pregnancy. Only 35.9% of women who reported cannabis use during
pregnancy had a positive urine screen. Sensitivity and specificity of self-report compared
to urinalysis were 0.36 and 0.99. In this study, maternal self-report was collected at the
time of enrollment (usually in the first trimester of pregnancy) and retrospectively
assessed cannabis use either before pregnancy or during the last three months from the
date of enrollment, whereas urine samples were collected in early, mid, and late
pregnancy. No detailed description was provided how urine collection process took place
and which of the three urine reports related to the self-reported cannabis use.
Christmas et. al84. compared the efficacy of maternal questionnaire with urine toxicology
screens for the detection of substance use in 302 pregnant women presenting to a
university-based obstetric clinic. Extensive questionnaires including the details of past
and current maternal and paternal substance use were administered during the first
prenatal visits. Urine samples collected during the study period were analyzed for a
number of illicit substances like amphetamines, barbiturates, benzodiazepines,
cannabinoids, benzoylecgonine, opiates, methaqualone, phencyclidine, methadone,
propoxyphene, nicotine, and ethanol. Only 17 of the 41 patients (41.5%) who tested
positive on the urine screens had admitted current substance use during the interview.
Only 50% of self-reported current (use within last 30 days) had positive urine toxicology
screens. The authors did mention that the questionnaires were administered during the
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first prenatal visit. However, no information was provided about the timing of this first
prenatal visit. Moreover, information on urine sample collection was ambiguous and no
explicit urine collection time period was mentioned.
In another study by Horrigan85 et. al., the authors compared three different measures a)
self-report b) urine screens, and c) Substance Abuse Subtle Screening Inventory (SASSI)
in order to determine which combination of measures would yield maximum sensitivity.
SASSI used in this study consists of two separate screens: first logically derived 26 face
valid items (scored 0 to 3) and second 52 true/false empirically derived items. The 78
items of the SASSI are divided into four clinical subscales: Face Valid Alcohol (FVA),
Face Valid Other Drugs (FVOD), Obvious Attributes (OAT), and Subtle Attributes
(SAT); two defensiveness subscales: Defensiveness subscale (DEF) and Supplemental
Addiction Measure (SAM); and two to three supplementary subscales: Random Answer
Pattern 56, Corrections subscale (COR), and Family Problems subscale (FAM), depending
on the version of the questionnaire. The authors found that the 54.7% of the sample was
positive for drug use by any one method. Self-reports identified 15.2% of users, whereas
urinalysis identified 17.3% users and SASSRI yielding highest sensitivity, identified
43.4% users.
Bibb et. al.86 evaluated the prevalence of illicit substance use and compared drug
screening results from maternal interview, meconium, maternal and newborn urine
analysis in 580 mother-newborn pairs. Maternal self-reports for the use of
tetrahydrocannabinol (THC) was positive in 5.7% delivering mothers, whereas only 2.5%
were positive from urine drug analysis and 1% newborns had positive meconium results.
Urine screens were less sensitive in the study as samples for biochemical verification and
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self-reported data were collected at the same time, which was after delivery. This might
not have captured all drug users in urine analysis. For cocaine, interview, maternal urine,
and meconium identified equal number of users (3.4%).
Lindsay et. al. 87 determined the accuracy of self-reported cocaine use in an urban
sample of 5200 pregnant women. In this large sample of pregnant women, only 5% tested
positive for cocaine use and 47% of the women with positive urine test acknowledged
drug use during the interviews, thus revealing a poor correlation between self-reported
cocaine use and the results of urine assays for cocaine metabolites among prenatal care
seeking pregnant women.
Yonkers et. al.88 compared self-reported marijuana or cocaine use in168 women enrolled
in an integrated obstetrical/substance abuse treatment program. They found good
agreement between the urine screens and self-reported use of cocaine and marijuana in
this population, k= 0.74 for marijuana and k=0.70 for cocaine respectively. The good
agreement between the measures could be attributed to the time frame of analysis as this
study captured drug use in past month from the interview and urine collection process.
2.3.2. Self-Report and Umbilical Cord Analysis
One study conducted by Wright et. al.89 evaluated the agreement between umbilical cord
analysis and maternal self-reports for cotinine and drug levels. The commonly reported
drugs used during pregnancy were methamphetamines, marijuana, and cocaine. The
authors found fair agreement between maternal smoking reports and cotinine levels
(kappa = 0.26 (0.07–0.5)) and poor agreement for self-reported drug use and positive
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drug tests (kappa = 0.19 (−0.05–0.4)). Sensitivity of positive cord illicit drug levels was
32% and specificity was 85% compared with maternal self-report.
2.3.3. Self-Reports and Meconium Analysis
Four studies compared self-reported maternal drug use with meconium analysis of the
newborns and found highly discordant results. Ostrea et. al.90 compared the sensitivity
and specificity of maternal interview, maternal hair analysis and meconium for cocaine,
opiate and cannabinoid use during pregnancy. This study showed that the interviews had
lowest sensitivity in detecting cocaine and opioid exposure (65% and 67%) but highest
sensitivity for cannabinoid exposures (58%) when compared to combined hair and
meconium analysis results. Hair analysis had a sensitivity of 100% for cocaine, 80% for
opiate, and 21% for cannabinoid detection when compared with combined interview and
meconium results. Meconium, on the other hand, had 87%, 77%, and 22.7% sensitivity
for maternal cocaine, opiates, and cannabis use, respectively when compared with
maternal interviews and hair analysis results. Sensitivity of self-report was moderate in
this study as these women knew that toxicology screens would confirm their self-reported
drug use.
Tassiopoulos et. al.91 compared self-reported prenatal substance use in a cohort of 480
HIV-infected women and their children with meconium analysis. Meconium samples
were available for 264 infants. Sensitivity of self-report was 80% for marijuana and 67%
for cocaine in this population using meconium analysis as gold standard. For a nonrandom subset of mothers/infants with urine/blood tests, higher discordance between selfreport and urine/blood toxicology was observed for cocaine, marijuana and opiates.
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Gray et. al.92 identified prenatal amphetamine exposure by maternal interviews and
meconium analysis in 3705 participants of the Infant Development, Environment and
Lifestyle (IDEAL) study. Based on the combination of maternal self-report and
meconium results, 5.7% of the neonates were amphetamine exposed; maternal selfreports identified 71% of the exposed, self-report and meconium analysis identified 25.2
% whereas meconium only identified 3.8% of the exposed infants. This study found
interesting results as maternal self-report was more sensitive in identifying drug exposure
compared to the meconium analysis. The reasonable explanation provided by authors for
these results was that the majority of this population had ceased their drug use in first or
second trimester, while meconium starts forming after 20 weeks of gestation.
Lozano et. al.93 estimated the prevalence of in-utero cannabis exposure in 974 motherinfants dyads by meconium analysis. Prenatal cannabis exposure was found in 5.3%
infants whereas only 1.7% mothers self-reported their use.
2.3.4. Self-Report and Hair Analysis
Bessa et. al94 assessed the validity of self-reported marijuana and/or cocaine use in the
third trimester in pregnant adolescent women using hair analysis. Hair analysis results
were positive in 6% of that study population: 4% for marijuana, 1.7 % for cocaine, and
0.3% for both. It was interesting to document that none of these patients had reported
their drug use in the interviews.
Grant et. al.95 compared 405 maternal postpartum hair samples with a structured maternal
interview conducted postpartum for the detection of cocaine use during pregnancy.
Cocaine or its metabolites were identified in 87% of women who reported using cocaine
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at least once during pregnancy. Among women who denied cocaine use in pregnancy,
14% had a positive hair test.

Summary
There is sufficient evidence supporting the notion that accuracy of self-reports for
behaviors like smoking, alcohol use, and illicit drug use during pregnancy is
questionable. Obtaining accurate information about substance abuse during pregnancy
poses a major challenge for healthcare providers and researchers working in this field.
Self-reporting, though convenient and easy to obtain, has its own limitations. Social
stigma, fear of losing the child, legal and social consequences of substance abuse during
pregnancy make it difficult to gather reliable information and hence appropriate
interventions may not reach the exposed infants and pregnant mothers.
In addition, accuracy of self-report may vary depending of the degree of social
desirability bias associated with each substance. As evident from the studies summarized
above, greater the social undesirability of a behavior, lower is the agreement between
self-reports and toxicology screens. Studies that have evaluated various risky behaviors in
the same population demonstrated lowest agreement for drug use followed by agreement
for alcohol and then tobacco.
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CHAPTER 3: METHODS
This chapter provides a detailed description of study design, methodology, and statistical
analysis.

3.1. Study Design and Population
This retrospective cohort study assessed the validity of patient self-reports by comparing
self-reported drug use during pregnancy provided by pregnant women against the results
of urine toxicology screens. Information provided by women enrolled in the study
regarding the use of marijuana, methadone, buprenorphine, prescription opioids and
heroin, amphetamines, cocaine, and benzodiazepines during a structured interview
conducted after delivery were compared with the results of the urine toxicology screens
conducted during the third trimester of pregnancy. For the purpose of this analysis, urine
toxicology screens were the criterion or gold standard, both terms used interchangeably.
Data collected from 102 pregnant women enrolled in the 'Biomarkers in Pregnancy
Study' (BIPS) at the University of New Mexico was utilized for this analysis. In brief,
BIPS is a prospective cohort study designed to assess the validity of several conventional
and novel ethanol biomarkers for accurate confirmation of alcohol exposure during
pregnancy. The study is approved by the University of New Mexico (UNM) Human
Research Review Committee (HRRC).
Pregnant women seeking prenatal care at the Milagro clinic, a specialized UNM clinic for
pregnant women with current or past substance use history, were enrolled for BIPS
during one of their prenatal visits by a bilingual study coordinator. To be eligible for
enrollment in this study, women had to give consent in either English or Spanish, be at
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least 18 years old, have an ultrasound confirmed singleton pregnancy, and be less than 35
weeks gestation at enrollment. Informed consent was obtained from all the eligible and
participating women. Detailed methodology of the parent study has been described
previously.96
Since these patients were recruited from a specialized clinic, majority of them were
recreational drug users. The vast majority were on opioid maintenance therapy (OMT)
receiving standardized doses of either methadone or buprenorphine.
During the BIPS study, two interviews were administered to the enrolled patients to
capture their general demographics, lifestyle habits, medical and reproductive history,
substance use including alcohol consumption during periconceptional and pregnancy
period, maternal and paternal smoking habits and illicit drug abuse. Baseline interviews
were conducted at the time of enrollment (mostly in the second trimester of pregnancy)
and then followed until labor and delivery. Follow-up interviews were conducted during
the hospital stay after delivery. Substance use information during the period between
baseline interview and delivery is collected in this second interview. Along with the
interviews, maternal biological samples including urine, serum, and whole blood were
collected at both baseline and follow-up visits. Repeated urine samples were collected
from these women during their treatment at the clinic and were analyzed for the
metabolites of various illicit and licit drugs at the TriCore Reference Laboratory
(Albuquerque, New Mexico).3.2. Measurements
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3.2.1. Demographics and Lifestyle Characteristics

Various sociodemographic characteristics included in this study were as follows:
maternal age (continuous variable), marital status (single/never married, married/living
with spouse, not married/living with partner, separated from spouse, divorced, widowed),
maternal ethnicity (Hispanic/Latina), race (White, Black or African American, American
Indian or Alaskan Native, Asian or Asian American Islander), education level (less than
high school grad, high school grad/GED, some college/vocational/ college degree,
masters/doctorate or professional degree), employment status (employed or not),
maternal insurance status (no insurance, employer-based, self-purchased, Medicaid, other
public insurances), place of birth (U.S. born or not), language mostly used at home
(English, Spanish or other).
Variables that ascertained maternal medical and reproductive history were as follows:
gestational age, pre-pregnancy weight, height, and BMI, presence of chronic conditions
(hypertension, diabetes, depression, anxiety, seizure disorder, migraine, rheumatoid
arthritis, thyroid, asthma/allergies, cancer, heart disease, hepatitis, liver/chronic biliary
conditions, tuberculosis, pancreatic disease or other). Additional questions on maternal
reproductive health were if this was a planned pregnancy (yes, not now, not any time),
parity (number of live-born children), gravidity (number of pregnancies including the
current one), history of miscarriage, still-born birth, terminations, ectopic pregnancy, and
any complications in the current pregnancy (bleeding, high blood pressure, diabetes,
other), use of medications and prenatal vitamins was also ascertained in the interviews.
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Lifestyle characteristics assessed in the interviews included smoking habits, alcohol use,
and illicit drug use. Women were asked to report their and their partners smoking status,
if they are current smokers, were past smokers and if they quit smoking before pregnancy
or after pregnancy and number of packets smoked daily.
Considering the objectives of the parent study, very comprehensive drinking information
was obtained from these enrolled women. Drinking habits in the periconceptional period
and during pregnancy were recorded by collecting information on binge drinking,
frequency of drinking, types of drinks during pregnancy, ‘high’ (number of drinks it takes
a person to feel high), and ‘hold’ (number of drinks a person can hold before passing out
or falling asleep) versions of the tolerance questions., Maternal biomarkers such as serum
gamma-glutamyltranspeptidase (GGT) and carbohydrate-deficient transferrin (CDT),
urine ethyl glucoronide (EtG) and ethyl sulfate (EtS), whole blood phosphatidylethanol
(PEth) and newborn PEth were analyzed in the samples both at baseline and follow-up to
ascertain alcohol consumption. Based on maternal self-reports and biomarker results, the
study sample was divided into a) Abstainers: self-reported abstainers with negative
biomarkers b) Early pregnancy exposure: Self-reported exposed with negative
biomarkers at delivery or self-reported controls with positive biomarker at enrollment c)
Chronic or late pregnancy users: women with positive biomarkers at the delivery.

3.2.2. Self-Reported Maternal Drug use
For the purpose of this analysis, information on maternal illicit drug use in the period
between enrollment and delivery is used. Structured follow-up interviews conducted
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post-delivery during the hospital stay captured maternal drug use in the period between
baseline and follow-up interviews. The responses from the follow-up interview formed
the basis of this analysis.
Follow-up interviews explicitly inquired the use of following classes of drugs: marijuana,
cocaine, crack-cocaine, heroin, methamphetamines, amphetamines, methadone,
buprenorphine, ecstasy, inhalants, prescription opiates, and benzodiazepines.
Enrolled pregnant patients were also asked to report the frequency of drug consumption
as one of the following categories: no use, occasional use (less than monthly), once a
month, once every 2 to 3 weeks, once a week, and almost every day.
Data Modifications:
Drug class modifications:
Few drug use variables employed separately in the interview that capture
information about the drugs of same classes were grouped together in the
analysis. Cocaine and crack-cocaine were grouped together as cocaine;
methamphetamines and amphetamines were categorized together because
methamphetamines are a part of amphetamine screening. Similarly, heroin and
prescription opiates were grouped together as they are tested under the same
toxicology screen.
Frequency of use modifications:
Follow-up interviews explicitly captured drug use frequency among one of the
following categories: no use, occasional use, once a month, once every 2 to 3
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weeks, once a week, and almost every day. As we cannot distinguish between
different drug use frequencies in qualitative urine screenings, self-reported drug
use were dichotomized as ‘no use’ and ‘any use’. Patients reporting occasional,
once a month, once every 2 to 3 weeks, once a week or almost every day were
categorized together as users. Hence, enrolled patients were categorized as either
non-users or users during the data analysis.

3.2.3. Urine Collection and Analysis
As mentioned previously, this study pertains to women attending the UNM Milagro
clinic, a specialized clinic for women with current or past history of substance abuse. The
majority of these women are on opioid maintenance therapy (OMT) and receive either
methadone or buprenorphine as therapy for their addiction since regulated and properly
administered OMT helps in improved outcomes, better prenatal and postnatal care. As
part of the protocol at the clinic, repeated urine samples are collected from these patients
during their prenatal visits and are analyzed at the TriCore Reference Laboratory for the
metabolites of commonly abused drugs. The results of the urine toxicology screens for
these patients are then entered in their electronic medical records at the clinic. These
repeated samples help in assessing the severity of addiction by prevalent co-exposures as
well as the compliance to the maintenance therapy.
'URINES DRUG of ABUSE SCREEN by MEDTOX® PROFILE-II: ER 12PANEL'97
was used to confirm the presence of drugs or their metabolites in the urine samples of the
enrolled women. MedTox Profile ER 12 Panel is a one-step colloidal metal
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immunochromatographic test for rapid and qualitative detection of twelve most common
classes of drugs of abuse or their metabolites in urine. Cut-off concentration for drug
detection in the urine samples and time windows for the various classes of drugs are
presented in Table 1. Results of these urine toxicology screens are then abstracted from
the electronic medical records of these patients.
Table 1: Drug Detection Concentrations and Time Windows

Drug

Cut-Off
Concentration

Detection Time
Window

CANNABINOIDS

50 ng/mL

3-7 days/ 30 days
for chronic users

MORPHINE

300 ng/mL

2-4 days

AMPHETAMINES

1000 ng/mL

1-5 days

METHAMPHETAMINES

1000-1500 ng/mL

3-5 days

COCAINE

300 ng/mL

2-5 days

METHADONE

300 ng/mL

3 days

BENZODIAZEPINES

300 ng/mL

7 days

OXYCODONE

100 ng/mL

1-4 days

Modifications:
Results of repeated urine toxicology screens were combined together in order to classify
these patients either as drug users or non-users. A patient was classified as a non-user for
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a particular drug if all of her toxicology screens from baseline to follow-up interview
were negative for the presence of drug metabolites for that specific class of the drug.
Similarly, users were defined by any positive urine toxicology screens for the metabolites
of the specific class of drug in the specified time frame as illustrated in the Table 2.
Table 2: Urine Toxicology Screen Outcomes and Interpretation
Toxicology Screen

Toxicology Screen

Toxicology Screen

Final

1

2

3

Interpretation

Negative

Negative

Negative

Negative

Negative

Positive

Negative

Positive

Positive

Positive

Negative

Positive

Positive

Positive

Positive

Positive

3.3. Graphical Representation of the Study Frame
As depicted in the Figure 1, majority of the baseline interviews were conducted in the
second trimester of the pregnancy. The baseline interview captured drug use since the last
menstrual period (LMP). Follow-up interview conducted after delivery captured drug use
since the baseline interview. Repeated urine screens that were conducted during the third
trimester would be compared to the drug use information provided in the follow-up
interview.
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Figure 1: Study time frame

3.4. Data Analysis and Outcomes Measures
3.4.1. Agreement between self-reported drug use and urine toxicology screens
The primary outcome of this study, that is the level of agreement between self-reported
drug use and urine toxicology screen results is evaluated by comparing self-reported drug
use in the period between the baseline and follow-up interviews with the urine toxicology
screens conducted in the third trimester of the pregnancy using kappa statistic.
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Sensitivity and specificity of self-reports for each class of drug is calculated using urine
toxicology screens as the 'gold standard'. Agreement for the purpose of this analysis is
represented in Table 3.
Table 3: Representation of Outcome
SELF- REPORT

URINE SCREENS

OUTCOME

YES

YES

AGREEMENT

NO

NO

AGREEMENT

NO

YES

DISAGREEMENT

YES

NO

DISAGREEMENT

3.4.2. Prevalence of Drug Use in the Milagro Population
Prevalence of use of cannabinoids, amphetamines, benzodiazepines, methadone,
buprenorphine, opioids including heroin was also estimated in the population attending
the Milagro clinic. Prevalence was estimated using self-reports and positive urine
toxicology screen results independently and then total prevalence was also estimated
using either measure, that is, all those who either reported drug use in their interviews or
were positive for drug use in the toxicology screens were considered as users for the
purpose of total prevalence estimation.
3.4.3. Effect of Number of Urine Toxicology Screens on Class-Specific Agreement
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Logistic regression was also performed to evaluate the effect of number of urine
toxicology screens on the class-specific agreement. Agreement for the purpose of
regression was defined as a binary variable and was represented as positive if both urine
toxicology screens and self-reports were positive and negative if both urine toxicology
screens and self-reports were negative for the same class of drug for the same patient.
3.4.4. Kappa Statistic 98
The agreement or concordance between self-reported drug use and positive urine
toxicology screens during pregnancy would be assessed using the kappa statistic. It is a
common measure of precision (reliability) between different observers that takes
agreement occurring merely by chance into account98,99. Kappa statistic applies to both
objective measures like radiographs, urine toxicology screens and to subjective
measurements like self-reporting. Comparing self-reported drug use with the presence of
drug metabolites in urine will assess the validity of self-reported drug consumption
during pregnancy.
Calculations:
Kappa coefficient is based on the difference between observed agreement and how much
agreement would be expected to be present by chance alone. As shown in figure 2, a 2X2
table is used to calculate kappa coefficient.
In the figure below, cells (a) and (d) represent the number of cases when there was
agreement between the two measures, that is, urine toxicology screens (gold standard)
and self-report while cells (b) and (d) represent the number of times when the two
measures disagree for the outcome of interest. Now it is possible that the two measures
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might sometimes agree just by chance. Kappa provides a numerical rating of the degree
to which this occurs and it is based on the difference between the observed and expected
(by chance alone) agreement. The observed agreement is the percentage of all the cases
when the different measures agree, in the example above, it can be represented by the
sum of (a) and (d) divided by total cases, N.
Kappa statistic measures differences in the observed agreement from the expected
agreement and its value is standardized to lie on a scale of -1 to 1.
Figure 2: Calculation of kappa statistic
Urine Toxicology Screens

Self-Report

Positive (+)

Negative (-)

Total

Yes

a

b

a+b

No

c

d

c+d

Total

a+c

b+d

Kappa statistic (k) = observed agreement (Po) - expected agreement (Pe)
1-expected agreement
where, observed agreement, Po = (a+d)/N
expected agreement, Pe = {(a+c) (a+b) + (b+d) (c+d)}/ N2
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If there were no agreements between the urine toxicology screens and self-report, then (a)
and (d) would be 0 and hence observed agreement would be 0. On the other hand, if there
were no disagreements, cells (b) and (c) would be 0 and the observed agreement is 1.

Figure 3: Interpretation of kappa

Different authors have suggested several classifications for interpreting the value of
kappa statistic. For the purpose of this analysis, we will be using the scale proposed by
Landis and Koch98. According to it, a perfect agreement would equate to a kappa statistic
of 1 whereas any value between 0.81 and 0.99 would indicate almost perfect agreement.
Similarly, kappa values between 0.41-0.60 indicate moderate agreement and values
between 0.61-0.80 indicate substantial agreement. Values from 0.20-0.40 indicate fair
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agreement and any value less than 0.20 is slight agreement and value of 0 represents
agreement due to chance and negative values, on the other hand, indicate agreement less
than chance. Various kappa values and their interpretation in tabular form are presented
in Table 4.

Table 4: Interpretation of Kappa statistic
Kappa value

Interpretation

1.00

Perfect agreement

0.81-0.99

Almost perfect

0.61-0.80

Substantial agreement

0.41-0.60

Moderate agreement

0.21-0.40

Fair agreement

0.0-0.20

Slight agreement

>0.0

Agreement less than chance

3.4.5. Prevalence-and-Bias-Adjusted Kappa (PABAK)
Although kappa coefficient is a widely used statistic to measure agreement between
raters, it suffers from certain limitations, most importantly its dependence on prevalence.
When the prevalence of a rating in the population is very high or low, the value of kappa
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may indicate poor reliability even with a high-observed proportion of agreement. For
example, it may signify low kappa even when the proportion of observed agreement is
relatively high or vice versa. This interesting phenomenon where the observed proportion
of agreement is high but the value of kappa statistic is low, is known as kappa
paradox100,101. If this paradox is present in the data and only simple kappa coefficients are
used to interpret the level of agreements, this may give misleading results. In order to
overcome this limitation of the kappa coefficient, another statistic PABAK is proposed
which adjusts the kappa for imbalances caused by differences in the prevalence and bias
101

.

The effect of prevalence can be assessed by estimating prevalence index that is calculated
as:
P.I. = | a-d | / N
If the prevalence index is high (ie, the prevalence of a positive rating is either very high
or very low), chance agreement is also high and kappa is decreased accordingly100,101.
Bias index is the extent to which raters disagree on the proportion of positive (or
negative) cases and is represented as 100:
B.I. = | b-c | / N
Kappa is higher when the bias index is high. In contrast to prevalence, the effect of bias is
greater when kappa is small than when it is large. As with prevalence, the magnitude of
kappa should be interpreted in light of the bias index. 100,101.
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PABAK adjusts for high or low prevalence by substituting the actual values of cells a and
d with their average values. Similarly, for bias, values of the cells b and c are substituted
with their average values.
Although, there is as such no criterion for the use of PABAK, however, when the
prevalence and/or bias index is high in the observations, then PABAK (along with simple
kappa, prevalence index, bias index, observed agreement and expected agreement) should
be reported.
3.4.6. Sensitivity and Specificity102
In addition to the measures of agreement, the validity of self-reports is also ascertained
by calculating sensitivity and specificity of self-reports for the above-mentioned classes
of drugs. They refer to the extent to which self-report measures what it is supposed to
measure, in other words, they ensure the accuracy of self-reports using urine toxicology
screens as the 'gold standard'. We would like to address that although there is no true gold
standard, we will be using urine toxicology screens as the gold standard since it is the
currently best available method of diagnosing and we will be validating self-reports using
them. The figure below illustrates the concept of sensitivity and specificity:
Figure 4: Sensitivity and Specificity
Urine Toxicology Screens (Gold Standard)

Self-Report

Yes

Positive (+)

Negative (-)

Total

True Positives

False Positives

a+b
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No

Total

(a)

(b)

False Negatives

True Negatives

(c)

(d)

a+c

b+d

c+d

Where, True postitive: the patient who has the disease and the test is positive
False positive: the patient who does not have the disease but the test is positive
True negative: the patient does not have the disease and the test is negative
False negative: the patient has the disease but the test is negative.

Sensitivity of a test is the ability of that test to correctly identify patients with the
outcome of interest. In other words, it is a measure of how likely it is for a test to pick up
the presence of the outcome of interest in a person who has it. It is calculated as the
proportion of true positives and the sum of true positives and false negatives.
Sensitivity =

True positives
True positives + False negatives

Specificity, on the other hand, is the ability of a test to correctly identify those patients
without the outcome of interest. It is calculated as the proportion of true negatives and the
sum of true negatives and false positives.
Specificity =

True negatives
True negatives + False positives

A test with 100% sensitivity correctly identifies all patients with the outcome of interest.
A test with 75% sensitivity will detect 75% of patients with the outcome of interest (true
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positives) but 25% with the outcome of interest will go undetected. Similarly, a test with
100% specificity accurately identifies all patients without the outcome of interest and a
test with 75% specificity correctly reports 75% of patients without the outcome of
interest as test negative (true negative) but 25% patients without the outcome of interest
are incorrectly identified as test positives (false positives).
Assessing sensitivity and specificity of self-report for various classes of drugs will help in
demonstrating that self-report is sensitive and specific and detects differences believed to
exist between groups of patients. We will be more confident that it is valid and measuring
what we believe it to measuring.

3.5. Power Analysis
The power analysis for this study was conducted in PASS software (Kaysville, Utah) for
comparing two independent proportions. For this analysis, alpha value that is the
probability of rejecting a true null hypothesis was set to be 0.05, and 0.2 for beta which is
the probability of accepting a false null hypothesis. Sample allocation was set at one, as it
was assumed that the sample size in both the groups would be same. For the purpose of
this power calculation, sensitivity of self-report for methadone was assumed to 99% as
women enrolled in this study are on opioid maintenance therapy and it was assumed that
self-reporting for methadone would be almost perfect. Power calculations are presented
for different effect sizes by varying the sensitivity of self-reporting for other classes of
drugs by 5% as difference in the sensitivity of self-report of methadone and other drug
classes is unknown.
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Table 5: Sample size calculations for different effect sizes
Power

Required sample
size

Sensitivity of
another drug class

Sensitivity of
methadone

0.85

22

0.50

0.99

0.82

24

0.55

0.99

0.83

28

0.60

0.99

0.81

32

0.65

0.99

0.80

38

0.70

0.99

0.81

48

0.75

0.99

0.80

62

0.80

0.99

0.81

90

0.85

0.99

0.80

178

0.90

0.99

Assuming the sensitivity of self-report for methadone to be 0.99, the required sample size
might vary form 22-178 depending on the detected differences between the sensitivities
of self-report for methadone and another drug class. A sample size of 22-32 patients will
achieve >80% power to detect a difference between the group proportion of 0.49- 0.34
using two sided Z test at alpha level 0.05.
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Chapter 4: RESULTS
This chapter summarizes the results of the study. A description of the study population's
socio-demographic, lifestyle characteristics along with medical and reproductive history
of the study population is presented. In the subsequent section, kappa and PABAK for
different classes of drugs are estimated and then in the end, sensitivity and specificity of
self-report for different classes of drugs are reported.
4.1. Description of the Study Population
Table 6 and 7 present descriptive characteristics of the study population including sociodemographic, lifestyle and medical and reproductive history variables.
4.1.1. Demographic Characteristics
The maternal age of the study sample ranged from 18 to 41 years with a mean of 26.4 ±
4.9 years. Majority of the patients were enrolled during the second trimester of their
pregnancy represented by a mean gestational age of 20.9 ± 7.9 weeks at enrollment. More
than three-fourths of the study population was comprised of ethnic minorities with 77.5%
Hispanic/Latina women. Majority of these women were White (86%) with much lower
proportion of American Indian (8.9%) and Black or African American (4%) in the
sample. Half of the study population was single/never married (54%), 38% were
married/not- married and living with a partner, and 8% of the patients were either
divorced, separated or widowed. In addition, approximately half of the enrolled
population was less than high school graduate (51.5%) and only 11.8% were currently
employed. Majority of these women were on either Medicaid or other public insurance
(95%) with 1% reporting an employer-based or self-purchased insurance and 4%
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reporting no insurance coverage. This population majorly comprised of U.S.-born women
(98%) and 97% reported English as their as their primary language.
4.1.2. Lifestyle Characteristics
The lifestyle characteristics of the enrolled population are also presented in Table 6.
Approximately 62% women reported being current smokers at the time of the interview
and 64% reported that their partners smoked. Approximately 80% women reported
smoking sometime during pregnancy and this number included both current smokers and
those who quit after realizing that they were pregnancy. A total of 20.5% women reported
no smoking during pregnancy, including non-smokers and those who quit before
pregnancy. Alcohol consumption information is also presented in the same table.
Based on both self-reported and biomarker measures, 45% of the sample abstained from
alcohol during pregnancy, 35% had early pregnancy alcohol exposure, and 20% were
chronic or late pregnancy alcohol users.
4.1.3. Medical and Reproductive History
The maternal medical and reproductive history of the enrolled sample is presented in
Table 7. More than a third of the study sample (37%) reported the presence of a chronic
condition(s), which was defined as a medical condition that requires repeated, ongoing,
or occasional treatment. The most common chronic conditions in this population included
anxiety (19%), depression (16%), hepatitis (15%), migraine (5%), and asthma (4%).
Other complications reported during pregnancy included bleeding (8%), high blood
pressure (2%), and other complications (6%) including nausea, placenta abnormalities,
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and fetal growth restriction. More than half of the study population (59%) reported
history of an adverse perinatal outcomes including stillbirth (3%), termination (26%),
miscarriage (46%), or ectopic pregnancy (5%). Approximately 52% of the patients had
their BMI in the healthy range (18.0 to 24.9) with 138.3±30.6 pounds mean prepregnancy weight and 63.5 ±4.0 cm mean height. About 88% of all women reported
using multivitamin and iron supplements during their pregnancy. For one fourth of the
study population (25%) this was their first pregnancy and 85% patients reported their
current pregnancy to be unplanned.
4.2. Prevalence of Illicit Drug Use and Opioid-Maintenance Therapy
The prevalence of various drugs of abuse were estimated using both measures (self-report
and urine toxicology screens) separately and then together using either measure. The
results are presented in Table 8. Methadone and buprenorphine were the most prevalent
with 63.85% and 62.07% prevalence, respectively. They were followed by marijuana and
cocaine with 25.3% and 24.1% of the enrolled women reporting their use, respectively.
Amphetamine and benzodiazepines were the least prevalent drugs with 9.5% and 6.0%
prevalence. Self-reported drug use prevalence was lower than the total prevalence
captured by either measure for all classes of drugs except methadone and
benzodiazepines.
In addition to prevalence, frequency of drug use stratified as no use, occasional use, once
a month use, once every 2 to 3 weeks use, once a week, and almost everyday use is
presented in Table 9 according to the drug classes. While majority of the study
population reported no drug use for all the classes (>80%) except for methadone (35%).
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Methadone and buprenorphine were used almost every day by maximum proportion of
women (64% and 17.2% respectively) compared to other drug class. Inhalants and
ecstasy were almost non-prevalent in this population. Cocaine, opioids, and
benzodiazepines had users in all the categories of the frequency.
4.3. Effect of Number of Urine Toxicology Screens on Drug Class-Specific Agreement
The mean number of urine toxicology screens conducted during the third trimester of
pregnancy in the study population was 4.8±3.0 per patient (range: 1-14).
4.4. Measures of Agreement and Validity
For measures of agreement, simple kappa coefficients with 95% confidence intervals,
prevalence-adjusted-bias-adjusted kappa (PABAK) coefficients, and proportion of
observed and expected agreement along with prevalence index and bias index were
estimated according to the drug classes and are presented in Table 10.
Methadone: As majority of these patients were on opioid maintenance therapy receiving
supervised doses of either methadone or buprenorphine for their addiction, a perfect
agreement was observed between self-report and urine toxicology screens for methadone
use during pregnancy (kappa and PABAK=1).
Buprenorphine: Being the alternative drug for opioid maintenance therapy,
buprenorphine was the second most prevalent drug in this population. The simple kappa
coefficient value for agreement between self-report and urine toxicology screens for
buprenorphine use during pregnancy was 0.79 (0.57; 1.00) indicating substantial
agreement. After adjusting for prevalence and bias index, the PABAK value remained
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same, 0.79 signifying substantial agreement between the two measures after adjusting for
prevalence. In contrast to an expected proportion of agreement equaling 0.50, the
observed proportion of agreement was 0.90 with 0.91 and 0.88 proportion of positive and
negative agreement respectively. The prevalence and bias index for buprenorphine were
0.14.
Cocaine: Kappa coefficient between self-report and toxicology screens for cocaine use
was 0.55 (0.32; 0.79) indicating moderate agreement. The PABAK value was 0.73
indicating substantial agreement between the two measures after adjusting for prevalence
and unequal distribution in the 2X2 tables. The expected and observed proportions of
agreement were 0.71 and 0.87 respectively with 0.62 and 0.92 proportion of positive and
negative agreement respectively. The prevalence index was -0.65 and bias index equal to
0.11. There were no differences in the PABAK values of the occasional and regular
users, 0.72 and 0.74, respectively.
Marijuana: The simple kappa coefficient for marijuana was 0.61, which after adjusting
for prevalence and bias changed to 0.76 signifying substantial agreement between the two
measures for marijuana use during pregnancy. The expected and observed proportions of
agreement were 0.69 and 0.88 respectively with 0.69 and 0.93 proportion of positive and
negative agreement respectively. The prevalence index was -0.61 and bias index equal to
0.07. Moreover, there were no differences in the PABAK value of the occasional and
regulars, 0.75 and 0.76 respectively.
Benzodiazepines: The kappa coefficient for agreement between self-reports and
toxicology screens for benzodiazepines indicated a fair agreement (k=0.36, CI: -0.04;
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0.76). However, after adjusting for low prevalence of benzodiazepines use in this
population, PABAK values of 0.86 represented almost perfect agreement between the
two measures. Moreover, the expected and observed proportions of agreement were 0.89
and 0.93 respectively with 0.40 and 0.96 proportion of positive and negative agreement
respectively. The prevalence index was -0.88 and bias index equal of 0.
Amphetamines: Similarly, to benzodiazepines, the value of simple kappa coefficient for
amphetamines represented fair agreement between the two measures (k=0.52, CI: 0.16;
0.88). However, PABAK value of 0.88 indicated an almost perfect agreement between
self-reported drug use and urine toxicology screens. In addition, the expected and
observed proportions of agreement were 0.87 and 0.94 respectively with 0.55 and 0.97
proportion of positive and negative agreement respectively. The prevalence index was 0.87 and bias index equal of 0.06.
4.5. Sensitivity and Specificity of Self-Reports
The sensitivity and specificity of self-report using urine toxicology screens as the gold
standard are presented in Table 11. While both the sensitivity and specificity of selfreport for methadone use during pregnancy was 100%, the sensitivity of self-report for
buprenorphine was slightly lower than that of methadone at 83%. Sensitivity of selfreport for marijuana (57.9%) and opioids including both prescription opioids and heroin
(58.3%) was similar, however their specificity varied with 97% and 90%, respectively.
Cocaine, benzodiazepines, and amphetamines had lowest sensitivity values of 47%, 40%
and 37%, respectively, although specificity of self-report for these drugs was almost
perfect (> 96%).

47

Additional subgroup analyses were performed by stratifying cocaine, marijuana, and
opioids users by occasional and regular user. This analysis revealed that the sensitivity of
self-reports decreases with increased use whereas specificity increases among frequent
users. For example, sensitivity of self-report for cocaine decreased from 33.3% to 28.6%
among occasional and regular users respectively whereas specificity increased from 98.4
to 100%. Similarly, the sensitivity of self-reports for opioids (47.1% to 16.7%) and
marijuana (42.9% to 38.5%) decreased whereas specificity of opioids increased from 89.7
% to 98.1% whereas there was no change for marijuana after stratifying as occasional and
regular users separately.
4.6. Effect of Number of Urine Screens on Agreement
Logistic regression was performed to evaluate the effect of number of urine toxicology
screens on the agreement between self-reports and urine toxicology screens (agreement
vs. no agreement) for each major class of drugs. Result of this analysis revealed no
association between the number of urine drug screens and the level of agreement, as
represented in Table 12.
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Chapter 5: DISCUSSION
This chapter first briefly summarizes the key findings of the study, followed by the
similarities and differences of the results with the existing literature. Limitations and
strengths of the study, implications of study findings along with the recommendations for
future research work then are discussed in the subsequent sections.
5.1. Summary of Key Findings
As the primary objective of the study was to assess the validity of self-reported drug use
during pregnancy for seven common drugs of abuse in a unique population of pregnant
women receiving prenatal care at a substance-abuse treatment clinic at the University of
New Mexico, simple kappa, PABAK coefficients, sensitivity and specificity were
estimated and reported. The values of PABAK indicated perfect agreement for
methadone use and substantial agreement for all other classes of drugs. Sensitivity of
self-reports for methadone use during pregnancy was 100% whereas it was slightly lower
for buprenorphine, 83%. While the sensitivity of self-reports was poor, with only slightly
more than half of the opioid and marijuana users reporting their use in the self-reports, it
was even poorer for cocaine, benzodiazepines and amphetamines.
The value of simple kappa coefficients indicated a varied level of agreement between the
two measures for the reported classes of drugs of abuse. The simple kappa coefficients
indicated perfect agreement for methadone. In other words, there was no discordance in
self-reported methadone use and the results of urine toxicology screens implying that
these women were indeed completely honest in admitting their methadone use during
pregnancy. The levels of agreement varied from almost perfect for buprenorphine use,
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substantial agreement for marijuana use, moderate agreement for cocaine, amphetamine,
opioids, and fair agreement for benzodiazepine use. However, as discussed previously,
one of the major limitations of simple kappa coefficient is its dependence on prevalence.
Thus, in order to overcome this limitation of the simple kappa coefficient, PABAK
coefficients were also calculated for the above-mentioned classes of drugs. In
concordance with the simple kappa, the value of PABAK for methadone indicated perfect
agreement. However, for all other classes of drugs, the value of PABAK between 0.6-0.8
indicated moderate to almost perfect agreement between the two measures. The similar
values of PABAK coefficients according to the classes of drugs and frequency of use
implied no differences in the self-reporting. Thus, the measure of agreement revealed a
good agreement between self-reports and urine toxicology screens.
Since kappa values are a function of sensitivity, specificity, prevalence and bias index
(ref1), sensitivity and specificity of self-reports for individual drug classes were also
reported. The 100% sensitivity and specificity of self-report for methadone use explains
no discordance in self-reports and urine toxicology screens. Sensitivity of self-report for
buprenorphine, being another choice of therapy, was lower than expected at 83%. One
plausible explanation for this could be the illicit use of buprenorphine (purchased without
prescription) by the enrolled patients. Sensitivity of self-report for opioids (prescription
and heroin) and marijuana was slightly higher (58.3% and 57.9%, respectively) than
other classes of drugs (ranging from 37.5% to 47.4%) indicating substantial
underreporting of drug use by the enrolled patients for marijuana, cocaine, opioids,
benzodiazepines, and amphetamines. Hence, large epidemiological studies merely relying
on self-reports as a measure of drug use assessment would be able to capture less than
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half of actual users. Moreover, as these women were recruited from a specialized clinic, a
higher degree of accuracy in reporting drug use during pregnancy is expected in this
population as opposed to the general OB/GYN population as these women are on therapy
for their addictions and have nothing to conceal. Thus, we expect sensitivity of self-report
to be even lower in the general population due to the social stigma attached with drug use
during pregnancy. Specificity of self-reports for all classes of drugs was close to 100%
except for opioids perhaps due to their short detection windows in the urine testing (See
Table 1). We here would like to acknowledge that even though detection window of
amphetamines is also short but the specificity of self-reports for amphetamine use was
high compared to opioids due to very few amphetamine regular users. We would also like
to acknowledge that the opioids given during labor and delivery will not affect the results
of this study as toxicology screens conducted before labor and delivery were included in
this study.
5.2. Previous Literature on Self-Reports and Urinalysis
The number of prior studies assessing agreement between self-reports and urine
toxicology screens for drug use during pregnancy are very limited and focused only on
cocaine and marijuana use during pregnancy. In the study conducted by Marroun et. al.,
the value of agreement between self-reports and urinalysis for prenatal cannabis use
(0.77) corresponded with the results of our study (0.76). However, the sensitivity of selfreports was 36%, much lower than our results (58%). A plausible explanation for this
finding in the Marroun's study was that it was conducted in a general Dutch population
with high educational levels (45% reported higher than secondary education) and low
prevalence of cannabis use during pregnancy (2.3%). Hence due to the social stigma
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attached with drug use during pregnancy, these women were less likely to admit their
cannabis use. Moreover, the results of the Marroun's study should be interpreted with
caution because of the methodological limitations in the study design. Self-reports,
collected at the time of enrollment retrospectively assessed cannabis use either before
pregnancy or during the last three months from the interview. The authors mentioned that
self-reports were usually collected in the first trimester of pregnancy, however, no
detailed information or data was provided on this. Urine samples in the Marroun study on
the other hand, were collected in early, mid and late pregnancy with 1-3 urine samples
per individual throughout pregnancy. In addition, the time interval between interviews
and urine collection was not reported.
Our measure of agreement is also similar to a study reported by Yonkers88 et.al. for
cocaine (0.73 and 0.70) and marijuana use (0.76 and 0.74) during pregnancy in a
substance abuse treatment population of 168 women. However, Yonkers found selfreports to be highly sensitive, 78% sensitivity for marijuana and 86% for cocaine in a
population comprised of majority of African-American. The time frame used in this study
was the past month from the interview whereas we captured last trimester of pregnancy
comprising of three months indicating higher sensitivity of self-report for shorter time
windows. Moreover, Yonkers utilized audio softwares for data collection on the
substance use, thus women were more open about their addiction as opposed to data
collected by healthcare/research staff. In the study conducted by Lindsay87 et. al. in an
urban sample of pregnant women, only 47% of the women with positive urine test
acknowledged their cocaine use during the interviews thus revealing low sensitivity of
self-reports for cocaine use during pregnancy in an urban sample of pregnant women
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seeking prenatal care. Although sensitive of self-report for cocaine use in this population
(47%) is in complete agreement with the sensitivity of self-report in our population
(47.3%), however, the two populations are completely different and hence comparison
may not be valid.
In another study by Christmas84 et. al., the sensitivity of self-reports for any drug use
during pregnancy was 41% with only 17 out 41 women admitting drug use in the
interviews. In that study, authors mentioned that the interviews were conducted during
the first prenatal visit; however, no information was provided about variability in the
timing of this prenatal visit. In addition, urine collection process and time-period were
not documented explicitly. The study evaluated self-reports for a number of drug classes,
however, only cumulative results for any drug use were presented, thus making the
comparison with the results of our study difficult.
Horrigan85 et. al. compared three measures, self-reports, urinalysis and substance abuse
subtle screening inventory (SASSI) in order to determine which combination of measures
would yield maximum sensitivity. SASSI consisted of two separate screens, first
comprised of 26 face valid items known as risk prediction scales and second is made up
of 52 true/false empirically derived items. Self-reports identified 15.2% of users, whereas
urinalysis identified 17.3% of users, and SASSRI yielding highest sensitivity by
identifying 43.4% of users. Although highly sensitive than urine screens and self-reports,
SASSI is a complex tool, which requires 15-20 minutes for the respondents for complete,
thus limiting its acceptability. Moreover, the circumstances under which self-reports, and
urine collection process took place were not elaborated in the article.
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The results of our study, however, are in complete disagreement with Bibb86 et. al. They
compared the validity of maternal interview versus drug screens conducted using
newborn meconium, newborn urine, and maternal urine samples for cocaine and
cannabis use. In that study, urinalysis or meconium screen were less sensitive for
identification of cannabis use than self-reports, as 5.7% of mothers admitted cannabis
use, while only 2.5% of maternal urine samples and 1% of meconium samples were
positive. Our explanation for this is the data collection time frames employed in this
study, as interviews and urine samples were collected after delivery. Interviews captured
drug use during pregnancy and urine analysis due to limited detection windows cannot
capture drug use throughout the pregnancy and as a result must have missed early
pregnancy drug use. With respect to cocaine use, maternal interview, urine and
meconium drug screens, all identified an equal number of users (3.4%). It is suspected
that these women may have underreported their cocaine use in the interviews as
urinalysis and meconium analysis may not have captured all the users owning to
methodological limitations in the urine collection timing and that meconium formation
does not take place until the second part of pregnancy. Long window of whole pregnancy
captured by interviews and one urine sample at the end of pregnancy make the results of
this study unreliable.
In summary, only one study has previously evaluated agreement between self-reports and
urine screens in pregnant population enrolled at a substance abuse treatment program.
Only two drugs were evaluated in that study (cocaine and marijuana) and only simple
kappa coefficients were estimated. Our study not only presents multiple measures of
agreement such as simple kappa, PABAK, sensitivity and specificity, but has a more
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robust study design with multiple urine screens in a trimester and evaluation of some
commonly abused classes of drugs.
In addition, the results of our study revealed higher sensitivity of self-report for opioids
and marijuana compared to the other classes of drugs. While none of prior study has
reported class-wise differences in the sensitivity of self-report in a population of pregnant
women, a very limited number of studies have estimated this in diverse populations. A
study conducted by Musshoff103 et. al. compared the results of urinalysis and hair
analysis with self-reported drug use data for opiates, cocaine, amphetamines, methadone,
and cannabinoids in drug users from a psychiatric clinic. The authors found that except
for opiates, all other drugs showed low correlation between self-reports and urinalysis. In
another study conducted by Ledgerwood 104 et.al., the sensitivity of self-reports
compared to hair analysis varied depending on the drug class with opioids self-report
exhibiting highest sensitivity (78%) and methamphetamine(44%) lowest sensitivity in the
same cohort of middle age men. Another study conducted by Glintborg105 et. al. assessed
the reliability of self-reports for amphetamines, barbiturates, benzodiazepines,
cannabinoids, cocaine, methadone and opioids use in a random sample of 100
hospitalized elderly medical patients. This study used a combination of urine and blood
sample for drug analysis and found 100% sensitivity of self-reports for opiates, which
however, should be interpreted with caution as sample of this study was hospitalized and
this could include only prescription opioids. The sensitivity of self-report for
cannabinoids in this population was 0% as none of the 5% users acknowledged its use.
No conclusion can be drawn from this as cannabinoids have relatively longer detection
windows (upto 30 days) and self-reports assessed use in the preceding one week
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timeframe. Sensitivity of benzodiazepines was also relatively low (53%) and remaining
drugs were almost non-prevalent in this population. In another study conducted by
Magura106 et. al. in 250 methadone treatment clients, they found opioid self-reports to be
least sensitive, whereas benzodiazepines and cocaine self-reports were moderately and
highly sensitive, respectively. In another study conducted by Lu et. al107. on a population
of arrestees that participated in the Arrestee Drug Monitoring program, the authors found
least amount of underreporting among the marijuana users with 64% sensitive selfreports using urinalysis, followed by methamphetamine (56%), cocaine (48%) and least
sensitive self-reports for opiates (45%).
In summary, some prior studies have demonstrated higher sensitivity of self-reports for
opioids and marijuana use compared to other classes of drugs; however others have
completely nullified this notion. Moreover, differences in the study population and cohort
characteristics, interview timings, framing of questions, and research methods make each
study unique and it is difficult to derive conclusions from the existing literature for our
unique population of pregnant women.
5.3. Limitations and Strengths
It is important to acknowledge that the urine toxicology screens conducted during the
third trimester of pregnancy were compared with the self-reported drug use which
captured the timeframe between the baseline and follow-up interviews. The average time
between the baseline and follow-up interviews was16.8 ±7.6 (range: 4-32) weeks. The
time-period captured by the interviews and detection window of urine screens do not
overlap completely and this may lead to potential misclassification bias. For instance, the
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results of urine screens conducted in the third trimester may lead to misclassification of a
user who accurately reported drug use in the early second trimester but then discontinued
use later on. This might lead to disagreement between the two measures owning to the
detection window of the urine screens. Moreover, detection windows for each drug class
vary with opioids (oxycodone, morphine) having the shortest detection window of 1-4
days and cannabinoids having the longest window of upto 30 days for chronic users.
However, the majority of patients were enrolled during the second trimester of pregnancy
(median gestational age at recruitment: 21weeks) approaching the timeframe captured by
urine screens. Moreover, the majority of women had multiple urine screens during the
third trimester (4.7 screens on average per patient) increasing the detection window. Our
results also demonstrated that the number of screens did not significantly affect the level
of agreement between the two measures.
We would also like to acknowledge that buprenorphine, methadone, and prescription
opioids were separate urine toxicology screens. This implies that someone who takes
buprenorphine would be negative for methadone or opiates but positive for
buprenorphine would require a separate test to be ordered.
We would also like to acknowledge that the use of brand names for the classes of drugs
evaluated in the study can contribute to the accuracy of self-reports. However,
street/common names of commonly abused drugs were mentioned in the questionnaire,
for example, buprenorphine and subutex were used for buprenorphine. Moreover,
common examples of prescription opioids were provided in the questionnaire to help the
respondents to accurately recall their use.
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Another limitation includes limited generalizability of the results of the study as the
sample was enrolled from a specialized prenatal clinic providing care to women with past
or current history of substance abuse. Thus, results might not be generalizable to the
general population of pregnant women. However, we expect that the sensitivity of selfreported drug use would be even poorer in the general population than in our study due to
the profound stigma attached with drug use during pregnancy. In the Milagro clinic, all
patients have already acknowledged their substance abuse and are actively seeking care
for it. Thus, it was surprising to find out that even in this population sensitivity of selfreport was rather poor for most drug classes except opioids and marijuana. This
underlines the need to supplement maternal reports with other methods in order to
accurately capture drug use in epidemiological studies.
We would also like to acknowledge that owning to the small sample size and low
prevalence of certain classes of drugs, such as inhalants and ecstasy; we were not able to
draw conclusions regarding the accuracy of their report during pregnancy. Low
prevalence of some other classes was adjusted for by estimating PABAK coefficients in
addition to a simple kappa coefficient. In addition, we cannot differentiate the accuracy
of self-report for use/abuse of prescription opioids and heroin since the urine toxicology
screen employed in the Milagro clinic did not differentiate between these subtypes of
opioids.
Unique strength of the study includes a well-characterized cohort comprising mostly of
ethnic minority. While prior studies were majorly comprised of either White or AfricanAmerican population we were able to capture a large proportion of Hispanic minority
with economically disadvantaged background. In addition, the study was able to assess
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the validity of self-reported drug use for multiple drug classes in a same cohort. Other
studies focused on one or two drug classes or lumped all drugs into a single ‘any drug
use’ category.

5.4. Implications and Future Recommendations

Accurate identification of illicit drug use during pregnancy offers unique opportunities
for both healthcare providers and pregnant women. This is an ideal time for healthcare
providers to help pregnant women in overcoming their drug addiction problems and thus
develop a healthy lifestyle, not only for themselves but also for their babies. However,
the social stigma attached with this issue might lead to the withholding of important drug
use information to the healthcare providers and hence appropriate care and therapy may
not be made available to these women. Accurate identification of drug use during
pregnancy is complicated and ensuring the accuracy of self-reports is important from
clinical and public health perspective, as it is the most inexpensive and commonly
employed method of data collection.
The result of this study indicate substantial agreement between urine toxicology screens
and self-reports; however, this should be interpreted with caution as agreement takes both
sensitivity and specificity into account and high specificity, a function of effective urine
screening process, may alter the results. Thus special attention should be paid to the
sensitivity of self-reports for drug use and our results reveal low sensitivity of self-reports
for all major classes of drugs despite the fact that these women were enrolled from a
specialty clinic and were aware of the purpose of the urine collection process. Moreover,
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as evident from the subgroup analyses of cocaine, marijuana, and opioids, the sensitivity
of self-reports was even lower among the regular users compared to occasional users. A
plausible explanation for this could be decreased willingness among regular users to
admit drug use during pregnancy owning to chronicity or severity of their addiction.
Hence, studies only relying on self-reports for drug use information during pregnancy are
very likely to suffer from reporting bias, more specifically underreporting. An approach
involving a combination of both self-reports and urinalysis for accurate identification of
prenatal drug use is suggested based on the evidence found in this study. However, in
circumstances when self-reports is the only mode of data collection, few measures can
that can improve the accuracy of self-reports include assuring confidentiality and
anonymity of the collected information, using skillful and emphatic interviewers or use of
audio-visual aids in case of sensitive information, using a short time interval between the
occurrence of actual event and the data collection process12.
Future studies focusing on different classes of drugs with adequate urine samples per
semester (weekly/fortnightly) in different populations are required. In addition, studies
examining the factors affecting the accuracy of self-reports in different populations, mode
and timing of data collection, stratification of study population as chronic and occasional
users would add to the gap in the literature.

Conclusions
In conclusion, the findings of our study revealed that pregnant women from a substanceabuse treatment clinic highly underreported their drug use during pregnancy. While
opioids and marijuana were more accepted than other drugs in this population, the level
of underreporting was substantial. We expect even lower sensitivity of self-reports for
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prenatal drug use in the general population. We found empirical evidence that it is
difficult to obtain valid prenatal drug use information by merely relying on self-reports. It
is highly likely that epidemiological studies merely relying on self-reported drug use data
would result in biased results and prevalence. Therefore, in order to improve the data
collection process on prenatal substance use, we suggest a 2-step approach involving both
self-reports and urinalysis.
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Table 6: Description of the Study Population
Patient Characteristics (N=102)
Maternal age (range: 18-41 years)
Gestational age at enrollment (weeks)
Gestational age at delivery (weeks)
Ethnicity: Latina

26.4 ± 4.9
20.9 ± 7.9
38.6 ± 2.1
%
77.5

Race:
White
American Indian
Black/African American
Other

86.1
8.9
4.0
1.0

Marital Status:
Single, never married
Married/ not-married, living with partner
Divorced/Separated/Widowed

53.9
38.2
7.9

Educational Level
Less than high school graduate
High school graduate or GED
College or higher

51.5
27.7
20.8

Employed

11.8

Health Insurance Status:
No insurance
Employer or self-purchased insurance
Medicaid or other public insurance

3.9
1.0
95.1

Primary language: English

97.1

Place of birth: US

98.0

Smoking
Any maternal smoking during pregnancy
No maternal smoking during pregnancy
Paternal smoking

79.4
20.5
63.7

Alcohol use
Abstainers
Early pregnancy
Continuous use

44.8
35.4
19.8
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Table 7: Maternal Medical and Reproductive History (N=102)

Medical and Reproductive Characteristics

Presence of chronic conditions
Hepatitis
Depression
Anxiety
Migraine
Asthma
Diabetes/ thyroid/ heart disease

%
37.3
14.7
15.7
18.6
5.0
3.9
1.0

Primigravida
Unplanned pregnancy
Healthy BMI (18.0-24.9)
Use of prenatal vitamins/ iron
History of adverse perinatal outcomes
Stillbirth
Termination
Miscarriage
Ectopic pregnancy
Complications in pregnancy
Bleeding
High blood pressure
Other

25.4
85.3
52.9
88.2
58.8
2.9
25.5
46.1
5.0
15.7
8.0
2.0
6.0
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Table 8: Prevalence of Drug Use in the Milagro Population N(%)

Self-Report

Toxicology
screens

Total
prevalence*

Marijuana

13 (15.7)

19 (22.9)

21 (25.3)

Cocaine

10 (12.0)

19 (22.9)

20 (24.1)

Methadone

53 (63.8)

53 (63.8)

53 (63.8)

Buprenorphine

15 (51.7)

18 (62.1)

18 (62.1)

Opioids**

20 (24.4)

24 (29.3)

30 (36.5)

Benzodiazepines

5 (6.0)

5 (6.0)

5 (6.0)

Amphetamines

3 (3.6)

8 (9.6)

8 (9.6)

*Total prevalence calculated using either measure, self-report or urine toxicology screen
** Opioids include both prescription opioids and heroin
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Table 9: Frequency of Drug Use during Pregnancy by Major Classes*, N (%)

Once a
month
2 (2.3)

Once
every 2
to 3
weeks
1 (1.2)

Once a
week
1 (1.2)

Almost
everyday
4 (4.6)

Marijuana

No use
73 (83.9)

Occasionally
6 (6.9)

Methadone

31 (35.6)

--

--

--

--

56 (64.4)

Buprenorphine¥

71 (81.6)

--

--

--

1 (1.2)

15 (17.2)

Amphetamine

84 (96.5)

1 (1.2)

--

2 (2.3)

--

--

Benzodiazepine

82 (94.2)

1 (1.2)

--

2 (2.3)

1 (1.2)

1 (1.2)

Cocaine

81 (93.1)

2 (2.3)

1 (1.2)

2 (2.3)

1 (1.2)

--

Opioids

72 (82.7)

8 (9.2)

2 (2.3)

--

2 (2.3)

3 (3.5)

Ecstasy

87 (100)

1 (1.2)

--

--

--

--

Inhalants

86 (98.8)

--

--

--

--

--

* Based on self-reports
¥
Sample size was 29 for buprenorphine as only these patients had urine toxicology screen
results for it.
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Table 10: Simple Kappa Coefficient, PABAK and Other Measures of Agreement.

Marijuana

N*

Prev
alen
ce**

Kapp
a

83

21

0.61

Expe
cted
agre
eme
nt

Obser
ved
agree
ment

Proporti
on of
positive
agreeme
nt

Proportio
n of
negative
agreemen
t

Prevalen
ce
index¥

Bias
indexα

PABAKƐ

0.41; 0.83

0.69

0.88

0.69

0.93

0.61

0.07

0.76

C.I.

Occasional use

77

0.51

0.21; 0.75

0.76

0.88

0.57

0.93

0.73

0.09

0.75

Regular use

76

0.51

0.23; 0.79

0.78

0.88

0.53

0.93

0.75

0.09

0.76

0.55

0.32; 0.78

0.71

0.87

0.62

0.92

0.65

0.11

0.73

Cocaine

83

20

Occasional use

79

0.41

0.14; 0.68

0.76

0.86

0.48

0.92

0.73

0.11

0.72

Regular use

77

0.40

0.12; 0.67

0.87

0.79

0.44

0.93

0.77

0.13

0.74

0.54

1.00

1.00

1.00

0.28

0

1.00

Methadone

83

53

1

Buprenorphine

29

18

0.79

0.57; 1.00

0.50

0.90

0.91

0.88

0.14

0.14

0.79

Opioids

82

30

0.50

0.29; 071

0.61

0.81

0.64

0.87

0.46

0.05

0.61

Occasional use

77

0.40

0.16; 0.64

0.65

0.79

0.53

0.87

0.56

0.05

0.58

Regular use

65

0.2

-0.07 ; 0.49

0.79

0.83

0.27

0.90

0.77

0.14

0.66

Benzodiazepines

83

0.36

-0.04 ; 0.76

0.89

0.93

0.4

0.96

0.88

0

0.86

83
8
0.87
Amphetamines
0.52 0.16; 0.88
* N is the sample with both self-reports and urine toxicology screens available

0.94

0.55

0.97

0.87

0.06

0.88

5

** Prevalence represents total prevalence estimated using either measure, self-report or urine screens
Ɛ
PABAK: Prevalence-adjusted-bias-adjusted kappa
¥
Prevalence Index: Difference in the proportion of positive and negative agreements
α
Bias Index: Extent to which the raters disagree on the proportion of positive or negative cases.
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Table 11: Sensitivity and Specificity of Self-Reports for Drug Use during Pregnancy

Simple kappa

PABAK

Sensitivity (%)

Specificity (%)

Marijuana

0.61

0.76

57.90

96.90

Cocaine

0.55

0.73

47.37

98.44

Methadone

1

1

100.00

100.00

Buprenorphine

0.79

0.79

83.33

100.00

Opioids

0.50

0.61

58.33

89.66

Benzodiazepines

0.36

0.86

40.00

96.15

Amphetamines

0.52

0.88

37.50

100.00
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Table 12: The Effect of Number of Urine Toxicology Screens on Class-Specific Agreement

Odds Ratio (C.I.)*
Marijuana

0.9 (0.8;1.2)

Cocaine

1.0 (0.8;1.2)

Opioids

1.1 (0.9;1.3)

Buprenorphine

1.1 (0.7; 1.6)

Benzodiazepine

1.0 (0.8; 1.3)

Amphetamine
0.8 (0.6; 1.1)
* Odds of agreement are modeled for one unit increase in urine toxicology screens.
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APPENDIX: DESCRIPTION OF STUDIES

69

AUTHOR

POPULATION/SAMPLE COMPARATORS

RESULTS

COMMENTS

ADVERSE EFFECTS OF IN-UTERO DRUG EXPOSURE

Mirochnick et. al16.

95 term cocaine (and/or
marijuana) exposed infants,
confirmed by
benzoylecgonine in
meconium.

Cocaine exposure and
impaired fetal growth.

70

Significant negative
correlations between
meconium benzoylecgonine
concentration and birth
weight, length and head
circumference

Restricted to full term
babies only.

Harsham et. al17

31 in utero exposed infants; In utero cocaine
predominantly black.
exposure and postnatal
growth pattern (for 1
year).
Reference populations: the
National Center for Health
Statistics (NCHS); 1991
Pediatric Nutrition
Surveillance System
(PNSS-all); Black infants
in PNSS (PNSS-black)

Shankaran et. al.

365 cocaine-exposed and
771 non-exposed infants;

Cocaine exposure and
SGA status (defined as
birth weight <10
percentile on the
Alexander curves)

71

Mean weight of the exposed Limited to infants in
infants at birth was
foster care eliminated
significantly lower than three
environmental effects.
reference populations
(p<0.01); mean length was
significantly lower than
NCHS and PNSS-all infants
(p<0.01). Mean length for
exposed infants was
significantly less than NCHS,
PNSS (p<0.01) and PNSSBlack (p<0.05)

Significantly lower growth
parameters in cocaine
exposed infants. Similar
weight at 6 years.

Self-reported nonexposure status
confirmed by
meconium analysis.

Significant interaction
between prenatal growth
exposure and SGA status at 6
years.

Matching: gestational
age, sex and race.

Bandstra et. al20.

476 neonates with in-utero
cocaine exposure

Cocaine exposure and
fetal growth and
gestational age

Cocaine associated growth
deficits were observed

African-American
population

Eyler et.al21.

154 cocaine exposed and
154 control mothers

Cocaine exposure and
neonatal outcomes

Significantly decreased head
circumference among
exposed infants.

Under-studied rural
public health
population

Minnes22 et. al.

156 prenatally exposed to
Cocaine exposure and
cocaine 6 year old children; growth parameters
131 high risk controls
along with dysmorphic
outcomes from birth
through 6 years of age.

Heavier prenatal exposure to
cocaine negatively affected
height and height for weight
z scores at age 6.

Considered various
levels of exposure:
non-exposed, light,
heavy, units per week
and meconium
threshold.

Bauer et. al23

Cocaine-exposed infants:

Cocaine exposed: 1.2 weeks

Multisite study with

Cocaine exposure
72

717 and 7442 non-exposed
infants

during pregnancy and
medical conditions in
newborn infants from
birth through hospital
discharge.

younger, less in weight,
smaller height and head
circumference. (all P<.001).

large sample size.

CNS and ANS symptoms
more frequent in the exposed
group as well as more
infections.

Ostrea et. al.6

44% of 2964 infants
positive for drugs.

Death outcome in drug
exposed infants

High perinatal morbidity and
high mortality in low weight
drug exposed infants.

High odds ratio for
sudden infant death
syndrome among
cocaine exposed (1.9)

Cherukuri et. al.9

55 crack using mothers and
55 non-drug exposed

Crack exposure and
fetal effects

Significant differences in
preterm births, intrauterine
growth retardation and
premature rupture of
membranes.

Mild neurobehavioral
symptoms among
crack exposed infants.

73

Fries et. al. 25

32 with prenatal cocaine
exposure referred to
genetics evaluation

Cocaine, alcohol
exposure and
Fetal effects

Distinctive phenotypes along
with premature births, smallfor-gestational age and
smaller head circumference

Distinctive diagnosis
for fetal cocaine
syndrome

40 cocaine exposed
neonates and 34 controls

Increased
neurosonographic
abnormalities in
cocaine exposed

35% cocaine exposed had
neurosonographic
abnormality compared to
none in controls

Degenerative changes
or focal infarctions in
basal ganglia of
cocaine exposed
neonates.

Behnke et. al. 28

311 cocaine exposed
infants matched to controls

Hospital costs
associated with
prenatal cocaine
exposures

Cocaine exposed: increased
healthcare services
utilization, longer lengths of
stay, and higher charges.

Population with
minimum access to
drug rehabilitation
services

Bandstra30 et. al.

Longitudinal Analysis of
451 full-term children;

Total, expressive, and
receptive language at
ages 3, 5 and 12 using
age-appropriate

PCE was associated with
lower expressive and total
language scores.

Children with prenatal
substance exposure,
except alcohol, tobacco
and marijuana were

Dogra et. al 26

242 cocaine-exposed and

74

209 non-exposed.

versions of the
Clinical Evaluation of
Language
Fundamentals (CELF)

Lewis et. al31.

175 PCE exposed children
and 175 non-exposed
children followed to 10
years of age

Language subscales of
the Test of Language
DevelopmentIntermediate 3rd
Edition (TOLD-I:3)
and phonological
processing measured
by the Comprehensive
Test of Phonological
Processing (CTOPP)

PCE cocaine effects were
observed for aspects of
language including syntax
semantics and phonological
processing (p=0.001)

Study sample limited
to African-American
children in
disadvantaged
neighborhoods.

Schuetze et. al32

Heart rate and respiratory
sinus arrhythmia (RSA) in
cocaine exposed and
control infants

Prenatal cocaine
exposure and
autonomic regulation
at 7 months of age

Cocaine exposed had higher
heart rate and significant
suppression of RSA.

Supported autonomic
dysregulation with
cocaine exposure.

75

excluded from the
analysis.

Lewis et. al.33

209 in utero cocaine
exposed and 189 nonexposed children

Prenatal cocaine and
polydrug exposure on
language development
of preschool kids.
Compared on
receptive, expressive
and total language
scores at 1, 2, 4 and 6
years of age.

Bandstra et. al. 34

200 cocaine-exposed and
176 non-exposed AfricanAmerican children

Longitudinal effects of
severity of prenatal
cocaine exposure on
language functioning
through age 7 years

76

Significant negative effect of
cocaine on all language
domains. Cocaine-exposed
children demonstrated
linguistic deficits compared
with non-exposed peers and
did not catch up.

Controlled for cigarette
and environmental
factors.

Greater severity of PCE was
associated with greater
deficits for language
performance (D = -0.071,
95% CI = -0.133, -0.009; p =
0.026).

Factors included in the
analysis were fetal
growth, gestational
age, and IQ as
intercorrelated
response variables and
child's age, gender, and
prenatal alcohol,
tobacco, and marijuana
exposure as covariates

Bateman et. al.19

240 healthy infants
Relationship between
exposed to cocaine exposed head circumference,
in third trimester.
birth weight, and
cocaine dose in
No exposure (n = 136), low prenatally exposed to
cocaine exposure (n = 52), cocaine infants.
and high cocaine exposure
(n = 52) by hair analysis

Mean birth weight, length,
and head circumference of
infants with high cocaine
exposure differed
significantly from those with
low exposure.

Birth weight, sex, and
high cocaine exposure
significantly associated
with newborn head
circumference

Morrow et. al36.

253 cocaine-exposed and
223 non-cocaine-exposed

Influence of PCE on
children's language
functioning at six time
points from 4 months
to 3 years of age.

Cocaine-exposed children
had lower overall language
skills than non-cocaineexposed children (D = 0.151; 95% CI = -0.269, 0.033; p =.012).

Remained stable after
evaluating
confounding by
prenatal substance
exposures and
sociodemographic
factors.

Bandstra et. al. 37

Urban sample of 236
cocaine-exposed and 207
noncocaine-exposed)

Longitudinal effects of
in utero cocaine
exposure on language

Significant association
between prenatal cocaine
exposure and deficits in total

Supported cocainespecific effect on
indicators of language

77

functioning at 3, 5 and
7 years of age

language functioning (D=0.17; 95% CI=-0.32, -0.03;
P=.019).

functioning during
early childhood
through age 7 years.

Singer et. al38.

131 Non-exposed children;
66 heavily exposed and 68
lightly exposed

Association of level of
fetal cocaine exposure
to developmental
precursors of speechlanguage skills at 1
year of age

Heavily exposed infants had
lower auditory
comprehension scores; more
likely to be classified as
mildly delayed by total
language score.

PCE led to attentional
disabilities underlying
auditory
comprehension.

Mentis et. al39.

5 prenatally cocaine
exposed children

Language
development and
cocaine exposure

Compromised language
development in cocaine
exposed infants

Analysis of 30 minute
language sample

Morrow et. al. 42

212 cocaine exposed and
197 non-cocaine exposed
children enrolled at birth

Risk of developing
learning disability or
impaired intellectual
functioning by age of

No differences in the
estimate of relative risk for
impaired intellectual
functioning between exposed

Results remained
stable with adjustment
for multiple child and
care-giver covariates

78

7 years

and non-exposed. However,
cocaine-exposed children had
2.8 times greater risk of
developing a LD by age 7
than non-cocaine-exposed
children (95%CI =
1.05,7.67; p = .038; IQ ≥ 70
cutoff)

Fajemirokunet. al. 51

110 babies born to 108
Opioids exposure and
women who used opiates in neonatal outcomes
later pregnancy

Significantly high likelihood Heroin using women
among neonates born to
with higher incidence
heroin using mother to need
of NAS
morphine than methadone
(40% vs 19%); high NAS
score (5.8 vs 4.7); longer stay
in neonatal units (17.2 days
vs 11.8)

Binder et. al52.

47 heroin, 32 methadone
and 38 buprenorphine
addicted pregnant women

Infants among heroin using
women had lowest birth
weight, highest proportion of
IUGR and placental change
(p < 0.05). The severity and

Effect of maintenance
therapy on neonatal
outcomes and NAS.

79

Methadone notably
protracted the
newborn's abstinence
syndrome.

course of NAS were most
severe (p < 0.001) in
newborns of women from the
methadone group.

Alrettaz et. al.53

86 neonates born to
mothers enrolled in
methadone maintenance
program.

Neonatal impact of
methadone use during
pregnancy.

24% babies were premature,
27% babies were growth
retarded (<3rd centile), and
13% had microcephaly (<3rd
centile). 62 % developed
NAS requiring
pharmacological treatment
for median 47 days.

Child services
involved in 56% cases
and 42% neonates
were placed outside
mother homes.

Greig et. al.59

44 pregnant women on
methadone and 88 non-

Maternal
and neonatal outcomes
of pregnant women

The MSP group higher
relative risk of premature
delivery, lower birth weight,

No difference in
congenital
abnormalities in the

80

methadone controls

enrolled in a
Methadone
Substitution
Programme (MSP)

smaller head circumferences

two groups; although
controls had higher
caesarean sections.

Broussard et. al. 62

17,449 mothers of kids
among cases with various
birth defects and 6701
control mothers

Association between
opioid use early in
pregnancy and birth
defects.

Statistically significant
association of opioid use
with conoventricular septal
defects atrioventricular septal
defects, hypoplastic left heart
syndrome, spina bifida or
gastroschisis

Commonly reported
opioids were codeine
hydrocodone
oxycodone and
meperidine

Bracken et. al. 63

1472 cases and 3001
controls

Exposure to
prescription opioids
during pregnancy and
congenital
malformations in

Case mothers were more
likely than controls to have
used a prescription drug
(odds ratio [o] = 13, P less
than .0001), particularly an

Incidence of congenital
malformations was 52
per 1000 live births
and 44% reported
using atleast one

81

newborns

antidepressant (o = 7.6),
narcotic analgesic (o = 3.6),
or tranquilizer (o = 23); all p
<0.01

prescription drug
during pregnancy.

Saxen et.al64.

599 children with clefts

Clefts and maternal
drug consumption
during pregnancy

More frequent consumption
of drugs among mothers of
infants with cleft lip.

Analgesic,
chemotherapeutic and
antineurotic more
frequent among cases.

Clearly et. al66.

117 pregnant women on
methadone maintenance
program

Perinatal outcomes
involving NAS
between methadone
users only and
concomitant polydrug
users.

Methadone-only exposed
neonate had shorter
hospitalization than those
exposed to methadone and
concomitant drugs (median
5.0 days versus 6.0 days, P
= 0.03)

The incidence and
duration of the NAS is
not associated with
maternal methadone
dose but maternal
polydrug use.

Hurt et. al. 108

PFC activation during task

Gestational cocaine

Similar performance on n-

Exposed and non-

82

Beeghly et. al. 109

performance in 25 cocaine
exposed infants and 24
non-exposed.

exposure and its
effects on prefrontal
cortex (PFC) with
functional magnetic
resonance imaging
(fMRI)

back task (P >/= .4),
indicating increased demands
on working memory with
greater task difficulty.
Region of interest images
showed similar activation for
both groups.

exposed were similar
in performance on the
executive function task
and in fMRI activation
patterns during task
performance.

160 low-income, urban
children from a prospective
study who completed a
standardized language
assessment at 6 and 9.5
years. PCE through
neonatal meconium assays
and maternal self-report.

Relationship between
prenatal cocaine
exposure and
contextual variables on
children's language at
age 6 and 9.5 years.

PCE children had lower
receptive language than
unexposed children at 6 but
not at 9.5 years. Also,

Age, birth weight, and
gender moderated the
relation between PCE
and language
development

83

lower expressive language
for lower birth weight, and
lower expressive and total
language if they were female

SELF-REPORT FOR RISKY BEHAVIORS AMONG PREGNANT WOMEN

Gollenberg77et. al.

82 women enrolled in the
periconceptional period

Smoking, caffeine,
fish, vitamins, alcohol.

Poor to moderate agreement.

Though higher for
regular behaviors like
caffeine and smoking.

Gilligan et. al.72

Women attending antenatal
care clinic.

Smoking and cotinine
levels in urine

17% self-reported nonsmokers misreported their
smoking status.

Error in smoking
assessment was
substantial

Shipton et.al.73

3475 pregnant women

SR smoking and blood
cotinine levels

SR led to an underestimation
of 25%

SR leads to failure to
detect 2400 smokers
each year for cessation
services.

84

Britton et.al.74

Klebanoff et.al.78

448 pregnant women
enrolled in a perinatal
project

SR smoking and
maternal cotinine
assays

High kappa coefficient
(k=0.83)

Pregnant women
accurately reported
their smoking status.

Secker-Walker79

Pregnant women

SR smoking, CO
levels, and
cotinine/creatinine
levels

Moderate correlations
between the measures

Urine
cotinine/creatinine
most accurate.

Ford et.al75.

Postal questionnaires to
4875 mothers
retrospectively

Questionnaires,
cotinine levels and
obstetric bookings

Underreporting in SR and
obstetric bookings

22% cotinine validated
denied smoking.

85

Burstyn et.al.76

92 smokers and

Self-reports and
urinary cotinine assays

Poor sensitivity (47%). High
specificity (95%)

Non-random sample of
women with live births

126 mothers with school
aged children

Pre and perinatal
maternal self-reports
with medical records

Good agreement for smoking
(k=0.80) whereas poor for
alcohol use (0.17)

Authors concluded
high validity of selfreports

700 pregnant women in a
randomized clinical trial
for a smoking cessation
intervention.

Alcohol and smoking
self-reports with
thiocyanate levels in
saliva

Moderate agreement for both
smoking and alcohol
drinking patterns during
pregnancy

Results may be biased
as participants were
aware about the
objectives of sample
collection.

SR alcohol, smoking

Low agreement for alcohol

Maternal

285 non-smokers (selfreported)

SR: Self-report; CO: Carbon monoxide;

Rice et. al80.

Fox et.al81.

86

Hessol et. al82.

350 Latina women

and various behavioral
and medical factors
with medical data

and smoking than for
medical conditions

characteristics did not
predicted patterns of
disagreement.

SELF-REPORT VS URINE SCREENS AMONG PREGNANT WOMEN

Marroun et. al. 83

Generation R study, a
population based birth
cohort to collect data on a
sample of parents and
children from early
pregnancy.

SR, UA

Moderate agreement
(Yule's Y=0.77)

Cannabis
Sensitivity and specificity
of self- report: 0.36 and
0.99.

Neither gold standard.

Two-step approach
starting with selfreport.

Sensitivity and specificity
of urinalysis: 0.46 and
0.98

UA: Urinanalysis

Christmas et. al.84

302 urban pregnant women
attending university based

SR, UA

Two-step approach
50 % self-reported use
87

obstetric clinic.
Alcohol/ any illicit
substance

had positive toxicology
screens;

41.5 % with positive
toxicology screen
admitted to current use.

Horrigan et. al.85

Bibb et. al86.

1276 pregnant women

580 mother infant pairs

Questionnaire
administered at the
initial visit; no such
information about
urine screens
(conducted during the
study period)

SR, SASSRI, UA

Self-report : 15.4 %

Cannabinoids, cocaine,
opiates, amphetamines,
barbiturates,
phencyclidines,benzodiaz
epines.

Urinalysis: 17.3 %

SR, UA, MA

THC: Self-report: 5.7%; In addition to
interview, maternal
maternal urine: 2.5 %
urine and newborn

88

No screening
procedure is better than
the other.

SASSRI: 43.4%

Tetrahydrocannabinol
(THC), phencyclidine
cocaine

Lindsay et. al87.

5200 women consented for SR and UA
urine assay

and meconium: 1%.
Cocaine: Equal
sensitivity (3.4%)

meconium should also
be incorporated.

47% with positive urine
assay acknowledged use
in self-report

Prevalence of cocaine
use: 5%

Marijuana (k)=0.74

Good agreement

Cocaine

Yonkers et. al88.

168 women substance
abuse treatment program
women

SR, UA

Cocaine
or marijuana
SASSRI: Substance Abuse Subtle Screening Inventory
; MA: Meconium
analysis

Cocaine (k)=0.70

Meconium

Ostrea et. al90.

Prospectively in 58 women

SR, meconium and
hair analysis

89

Lowest sensitivity of selfreports for cocaine and
opioids.

Meconium best
screening method
among the three
evaluated in this study

Cocaine, opiate,
cannabinoid

Tassiopoulos et. al. 91 281 HIV-infected women
and children

SR and meconium

Moderate Agreement

Marijuana

Sensitivity for self-reported
marijuana use: 80%
(kappa=0.61, p-value <0.01),
cocaine: 67% (kappa=0.80,
p-value <0.01).

Cocaine

Gray et. al. 92

Pregnant women in the
IDEAL study
Infant Development,
Environment and Lifestyle
(IDEAL)

SR and meconium
Methamphetamine
Cannabis

90

Self-report more sensitive
than meconium analysis for
amphetamine and cannabis
exposure

Sensitivity of SR
compared to urine or
blood toxicology: 31%
for cocaine, 30% for
marijuana and 20% for
opiates

Majority ceased the
use in first/second
trimester

Lozano et. al.93

974 mother-infants dyads

SR and meconium

5. 3% identified by
meconium whereas only
1.7% self-reported.

Check for SR timing?

SR , UCA

K=0.19

Methamphetamines

Sensitivity and Specificity of
cord levels: 32% and 85%

Cord had highest
sensitivity for
marijuana

Cannabis

SR: Self-report; UA: Urinalysis; MA: Meconium analysis

Umbilical Cord

Wright et. al.89

28 women admited drug
use

Cocaine
Marijuana

Hair

High prevalence according
91

Not a single person

Bessa et. al. 94

Pregnant adolescents

SR and Hair
Marijuana

to hair analysis and none
reported

accepted in self-report

Hair analysis identified 87%
self reported use.

Both measures for
gestational cocaine
exposure.

Cocaine

Grant et. al 95

405 post partum women

SR and hair

Cocaine
14% with negative SR were
positive with hair analysis.

SR: Self-report; UA: Urinalysis; MA: Meconium analysis

92
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